WO2020230833A1 - Nouveau composé polyterpénoïde ayant une action amplifiant l'activité d'un médicament antifongique, et sa méthode de production - Google Patents

Nouveau composé polyterpénoïde ayant une action amplifiant l'activité d'un médicament antifongique, et sa méthode de production Download PDF

Info

Publication number
WO2020230833A1
WO2020230833A1 PCT/JP2020/019174 JP2020019174W WO2020230833A1 WO 2020230833 A1 WO2020230833 A1 WO 2020230833A1 JP 2020019174 W JP2020019174 W JP 2020019174W WO 2020230833 A1 WO2020230833 A1 WO 2020230833A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
formula
hydroxyl
compound represented
Prior art date
Application number
PCT/JP2020/019174
Other languages
English (en)
Japanese (ja)
Inventor
洋 供田
聡 大手
Original Assignee
学校法人北里研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 学校法人北里研究所 filed Critical 学校法人北里研究所
Publication of WO2020230833A1 publication Critical patent/WO2020230833A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/145—Fungal isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/04—Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin, vitamin C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/66—Aspergillus

Definitions

  • the present invention relates to a novel polyterpenoid compound having an activity enhancing action against an antifungal drug and a method for producing the same.
  • one aspect of the present invention is a novel poly having an activity enhancing action of at least one antifungal drug selected from the group consisting of polyene macrolides, azoles, candins and fluoropyrimidines.
  • the present invention relates to a terpenoid compound and a method for producing the same.
  • antifungal drugs such as polyene macrolides, azoles, candins and fluoropyrimidines are used for the treatment of deep-seated mycoses.
  • amphotericin B which is one of polyene macrolides
  • fluoropyrimidines have strong antifungal activity and is therefore effective in treating serious diseases.
  • this drug may cause side effects such as nephrotoxicity, a safety problem has been pointed out (Non-Patent Document 1).
  • Flucytosine which is one of the fluoropyrimidine-based drugs, also has problems such as low safety and the presence of resistant bacteria.
  • Azole drugs are generally considered to have a wide safety margin and relatively few side effects. However, this drug has a narrow antifungal spectrum and exhibits a bacteriostatic mechanism of action, and thus has low efficacy for serious diseases. It has also been pointed out that the number of bacteria resistant to the drug has increased (Non-Patent Document 2).
  • Non-Patent Document 3 candy-based drugs such as micafungin and caspofungin have been developed and used for the treatment of deep-seated mycoses.
  • the drug has a narrow antifungal spectrum, the disease to be treated is limited to candidiasis or aspergillosis.
  • the number of reported cases of resistant bacteria to the drug is gradually increasing.
  • Patent Document 1 describes a novel FKI-4981B substance and a pharmaceutically acceptable salt thereof having an activity of enhancing the activity of at least one antifungal agent selected from polyene macrolide agents and azole agents. Describe. The document describes that the FKI-4981B substance can be used as an active ingredient in pharmaceutical compositions for enhancing the activity of these antifungal agents.
  • Patent Documents 2 and 3 are represented by the formula (I), which is a novel compound having an action of effectively enhancing the antifungal activity of an antifungal drug and having a skeletal structure different from that of a known pharmaceutical compound.
  • a compound having an action of enhancing the antifungal activity of an antifungal drug can reduce the dose of the antifungal drug and / or shorten the administration period. Therefore, by using a compound having such an action in combination with an antifungal drug, the dose of the antifungal drug is reduced and / or the administration period is shortened to suppress the occurrence of side effects such as nephrotoxicity. And / or the development of drug-resistant bacteria can be suppressed.
  • various compounds having the above-mentioned action various compounds such as FKI-4981B substance and a pharmaceutically acceptable salt thereof are known (Patent Documents 1 to 3). However, in order to develop a more effective pharmaceutical compound, a new compound having an action of effectively enhancing the antifungal activity of an antifungal drug and having a skeletal structure different from that of a known pharmaceutical compound is required. Was there.
  • an object of the present invention is to provide a novel compound having an action of effectively enhancing the antifungal activity of an antifungal drug and having a skeletal structure different from that of a known pharmaceutical compound.
  • the present inventors have studied various means for solving the above problems.
  • the present inventors have stated that a novel bacterium isolated from soil produces a compound in its culture medium that has an action of effectively enhancing the antifungal activity of amphotericin B, which is one of polyene macrolides. I found it.
  • the present inventors have found that the compound in the culture solution is a novel compound having a skeletal structure different from that of known pharmaceutical compounds.
  • the present inventors have found that the compound can be produced by a culturing means using the bacterium.
  • the present inventors have completed the present invention based on the above findings.
  • R 6 and R 7 are independent of each other, hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkoxy, substituted or unsubstituted heterocycloalkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted.
  • R 10a is hydrogen
  • R 11a is hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkoxy, substituted or unsubstituted heterocycloalkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted arylalkyloxy, substituted or unsubstituted.
  • Substituted arylalkoxyoxy, substituted or unsubstituted heteroaryloxy, substituted or unsubstituted heteroarylalkyloxy, or substituted or unsubstituted acyloxy, or R 10a and R 11a are covalently bonded together.
  • Form and R 14a is hydrogen
  • R 15a is hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkoxy, substituted or unsubstituted heterocycloalkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted arylalkyloxy, substituted or unsubstituted.
  • R 19 ', R 23', and R 27 ' are independently of one another, hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, Substituted or unsubstituted cycloalkoxy, substituted or unsubstituted cycloalkoxynyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted heterocycloalkylalkyl, substituted or unsubstituted aryl , Substituted or unsubstituted or unsubstituted
  • -And R 35a is hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkoxy, substituted or unsubstituted heterocycloalkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted aryl.
  • Alkyloxy, substituted or unsubstituted arylalkenyloxy, substituted or unsubstituted heteroaryloxy, substituted or unsubstituted heteroarylalkyloxy, or substituted or unsubstituted acyloxy, or R 31a is hydroxyl, substituted.
  • it is an unsubstituted heteroaryloxy, a substituted or unsubstituted heteroarylalkyloxy, or a substituted or unsubstituted acyloxy, and R 34a and R 35a together form a covalent bond.
  • R 19 ', R 23', and R 27 ' independently of one another, hydrogen, substituted or unsubstituted C 1 ⁇ C 6 alkyl, substituted or unsubstituted C 2 ⁇ C 6 alkenyl, substituted or With unsubstituted C 2 to C 6 alkynyl, substituted or unsubstituted C 3 to C 6 cycloalkyl, substituted or unsubstituted C 3 to C 6 cycloalkenyl, or substituted or unsubstituted C 3 to C 6 cycloalkynyl.
  • R 31a and R 34a together form -O-, and R 35a is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, or substituted or unsubstituted C 3 to C.
  • R 1 ' is hydrogen, R 6 and R 7 together form a covalent bond
  • R 10a is hydrogen and R 11a is a hydroxyl
  • R 10a and R 11a together form a covalent bond.
  • R 14a is hydrogen
  • R 15a is the hydroxyl
  • Solvation product. (7) A method for producing a compound according to any one of the above-described embodiments (1) to (6), a salt thereof, or a solvate thereof.
  • the fungal Aspergillus polypolycola BFM-0088 strain (receipt number NITE ABP-02936) capable of producing the compound represented by the formula (Ia) or a microorganism thereof is cultured in a medium and the formula (Ia) is used.
  • Fungal Aspergillus polypolycola BFM-0088 strain (receipt number NITE ABP-02936) having the ability to produce the compound represented by the formula (Ia) according to any one of the above embodiments (1) to (6).
  • R 1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkyl Alkinyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted heterocycloalkylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted Heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted alk
  • R 6 and R 7 are independent of each other, hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkoxy, substituted or unsubstituted heterocycloalkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted.
  • R 6 and R 7 together form a covalent bond
  • R 10 and R 11 are independent of each other, hydrogen, hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkoxy, substituted or unsubstituted heterocycloalkoxy, substituted or unsubstituted aryloxy, substituted or Unsubstituted arylalkyloxy, substituted or unsubstituted arylalkoxyoxy, substituted or unsubstituted heteroaryloxy, substituted or unsubstituted heteroarylalkyloxy, or substituted or unsubstituted acyloxy, or R 10 and R 11 together form a covalent bond or -O-, R 14 is hydrogen, R 15 is hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkoxy, substituted or unsubstituted heterocycloalkoxy, substituted or unsubstitute
  • arylalkyloxy substituted or unsubstituted arylalkoxyoxy, substituted or unsubstituted heteroaryloxy, substituted or unsubstituted heteroarylalkyloxy, or substituted or unsubstituted acyloxy.
  • R 31 and R 34 together form -O-, and R 35 is hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkoxy, substituted or unsubstituted heterocycloalkoxy, substituted.
  • Acyloxy or R 31 is hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkoxy, substituted or unsubstituted heterocycloalkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted aryl.
  • a medicament for use in the prevention or treatment of one or more fungal infections which comprises the antifungal activity enhancer according to the embodiment (9) or (10) as an active ingredient.
  • the drug described in any of. The compound according to any one of the above-described embodiments (1) to (6), a pharmaceutically acceptable salt thereof, or a solvate thereof, and one or more pharmaceutically acceptable salts.
  • a pharmaceutical composition comprising a carrier.
  • each aspect of the present invention it is possible to provide a novel compound having an action of effectively enhancing the antifungal activity of an antifungal drug and having a skeletal structure different from that of a known pharmaceutical compound.
  • alkyl means a linear or branched saturated aliphatic hydrocarbon group containing a specific number of carbon atoms.
  • C 1 to C 6 alkyl means a linear or branched saturated aliphatic hydrocarbon group containing at least one and at most six carbon atoms.
  • Suitable alkyls are linear or fractionated, such as, but not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl and n-hexyl. Branch chain C 1 to C 6 alkyl can be mentioned.
  • alkenyl means a group in which one or more CC single bonds of the alkyl are substituted with double bonds.
  • Suitable alkenyls include, but are not limited to, vinyl, 1-propenyl, allyl, 1-methylethenyl (isopropenyl), 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-2-propenyl, 2 C 2 -C 6 alkenyl with straight or branched chains such as -methyl-2-propenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-pentenyl and 1-hexenyl can be mentioned. ..
  • alkynyl means a group in which one or more CC single bonds of the alkyl are substituted with triple bonds.
  • Suitable alkynyls are, but are not limited to, for example, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 1-pentynyl and 1-hexynyl.
  • C 2 to C 6 alkynyls such as straight or branched chains can be mentioned.
  • cycloalkyl means an alicyclic alkyl containing a specific number of carbon atoms.
  • C 3 to C 6 cycloalkyl means a cyclic hydrocarbon group containing at least 3 and at most 6 carbon atoms.
  • Suitable cycloalkyls include, but are not limited to, C 3 to C 6 cycloalkyls such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • cycloalkenyl means a group in which one or more CC single bonds of the cycloalkyl are substituted with double bonds.
  • Suitable cycloalkenyl includes, but are not limited to, C 4 to C 6 cycloalkenyl such as cyclobutenyl, cyclopentenyl and cyclohexenyl.
  • cycloalkynyl means a group in which one or more CC single bonds of the cycloalkyl are substituted with triple bonds.
  • Suitable cycloalkynyls include, but are not limited to, C 4 to C 6 cycloalkynyls such as cyclobutynyl, cyclopentynyl and cyclohexynyl.
  • heterocycloalkyl means that one or more carbon atoms of the cycloalkyl, cycloalkenyl or cycloalkynyl are independently selected from nitrogen (N), sulfur (S) and oxygen (O), respectively.
  • N nitrogen
  • S sulfur
  • O oxygen
  • substitution with N or S includes the substitution with N-oxide or S oxide or dioxide, respectively.
  • Suitable heterocycloalkyls include, but are not limited to, for example, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrofuranyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl and piperazinyl. ⁇ 6 members of heterocycloalkyl can be mentioned.
  • cycloalkylalkyl means a group in which one of the hydrogen atoms of the alkyl, alkenyl or alkynyl is substituted with the cycloalkyl, cycloalkenyl or cycloalkynyl.
  • Suitable cycloalkylalkyls include, but are not limited to, C 7 to C 11 cycloalkylalkyls such as cyclohexylmethyl and cyclohexenylmethyl.
  • heterocycloalkylalkyl means a group in which one of the hydrogen atoms of the alkyl, alkenyl or alkynyl is substituted with the heterocycloalkyl.
  • Suitable heterocycloalkylalkyls include, but are not limited to, for example, 3- to 6-membered heterocycloalkyl-C 1 to C 6 alkyls.
  • alkoxy and alkoxyl mean a group in which a hydrogen atom of a hydroxyl group is substituted with the alkyl, alkenyl or alkynyl.
  • Suitable alkoxys and alkoxyls are, but are not limited to, C 1 to C 6 alkoxy or C such as, for example, methoxy or methoxyl, ethoxy or ethoxyl, propoxy or propoxyl, butoxy or butoxyl, pentoxy or pentoxyl, and hexoxy or hexoxyl. 1 to C 6 Alkoxy can be mentioned.
  • cycloalkoxy and “cycloalkoxyl” mean a group in which a hydrogen atom of a hydroxyl group is substituted with the cycloalkyl, cycloalkenyl or cycloalkynyl.
  • Suitable cycloalkoxys and cycloalkoxyls are, but are not limited to, C 3 to C 6 cycloalkoxy or C 3 such as, for example, cyclopropoxy or cyclopropoxyl, cyclobutoxy or cyclobutoxyl and cyclopentoxy or cyclopentoxyl.
  • ⁇ C 6 cycloalkoxyl can be mentioned.
  • heterocycloalkoxy and “heterocycloalkoxyl” mean a group in which a hydrogen atom of a hydroxyl group is substituted with the heterocycloalkyl.
  • Suitable heterocycloalkoxy and heterocycloalkoxyl include, but are not limited to, for example, 3- to 6-membered heterocycloalkoxy or 3- to 6-membered heterocycloalkoxy.
  • aryl means an aromatic ring group. Suitable aryls include, but are not limited to, C 6 to C 18 aryls such as phenyl, biphenyl, terphenyl, naphthyl and anthracenyl.
  • arylalkyl means a group in which one of the hydrogen atoms of the alkyl, alkenyl or alkynyl is substituted with the aryl.
  • Suitable arylalkyls include, but are not limited to, C 7 to C 20 arylalkyls such as benzyl, 1-phenethyl, 2-phenethyl, biphenylmethyl, terphenylmethyl and styryl.
  • heteroaryl means a group in which one or more carbon atoms of the aryl are independently substituted with one or more heteroatoms selected from N, S and O, respectively.
  • the substitution with N or S includes the substitution with N-oxide or S oxide or dioxide, respectively.
  • Suitable heteroaryls are, but are not limited to, for example, furanyl, thienyl (thiophenyl), pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiadiazolyl, isothiazolyl, pyridyl, pyridadinyl, pyrazinyl, 5 to 15 member heteroaryls such as pyrimidinyl, quinolinyl, isoquinolinyl and indyl can be mentioned.
  • heteroarylalkyl means a group in which one of the hydrogen atoms of the alkyl, alkenyl or alkynyl is substituted with the heteroaryl.
  • Suitable heteroarylalkyls include, but are not limited to, 5- to 15-membered heteroaryl-C 1 to C 6 alkyls such as pyridylmethyl.
  • aryloxy means a group in which the hydrogen atom of hydroxyl is substituted with the aryl.
  • Suitable aryloxys include, but are not limited to, C 6 to C 18 aryloxys such as phenoxy, biphenyloxy, naphthyloxy and anthryloxy (anthrasenyloxy).
  • arylalkyloxy means a group in which a hydrogen atom of a hydroxyl group is substituted with the arylalkyl.
  • Suitable arylalkyloxys include, but are not limited to, C 7 to C 20 arylalkyloxys such as benzyloxy, 1-phenethyloxy, 2-phenethyloxy and styryloxy.
  • heteroaryloxy means a group in which the hydrogen atom of hydroxyl is substituted with the heteroaryl.
  • Suitable heteroaryloxys include, but are not limited to, for example, furanyloxy, thienyloxy (thiopheneyloxy), pyrrolyloxy, imidazolyloxy, pyrazolyloxy, triazolyloxy, tetrazolyloxy, thiazolyloxy, oxazolyloxy, iso.
  • heteroarylalkyloxy means a group in which a hydrogen atom of a hydroxyl group is substituted with the heteroarylalkyl.
  • Suitable heteroarylalkyloxys include, but are not limited to, 5 to 15 members of heteroaryl-C 1 to C 6 alkyloxys.
  • acyl means a group in which a monovalent group selected from the groups described above and a carbonyl are linked. Suitable acyl may include, but are not limited to, such as formyl, acetyl and C 1 ⁇ C 6 aliphatic acyl, and C 1 ⁇ C 20 acyl includes C 7 ⁇ C 20 aromatic acyl of benzoyl propionyl, etc. Can be mentioned.
  • the groups described above can be independently unsubstituted or further substituted with one or more monovalent groups described above.
  • halogen or halo means fluorine (F), chlorine (Cl), bromine (Br) or iodine (I).
  • the present invention relates to a compound represented by, or a salt thereof, or a solvate thereof.
  • the present invention relates to an antifungal activity enhancer containing a compound represented by (1), a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient.
  • the present inventors have stated that a novel fungus isolated from soil produces a compound in its culture solution that has an action of effectively enhancing the antifungal activity of amphotericin B, which is one of polyene macrolides. I found it.
  • the present inventors have found from the culture solution the known compounds glycoprenin F having an activity of enhancing the antifungal activity of amphotericin B, and novel compounds glycoprenins G and H (hereinafter, also simply referred to as “glycoprenins”). It was. Glysoprenins F, G and H can significantly enhance the antifungal activity of amphotericin B when administered in combination with amphotericin B, although they do not exhibit substantial antifungal activity when administered alone.
  • the compound represented by the formula (Ia) of one aspect of the present invention includes novel natural organic compounds glycoprenins G and H, and related compounds thereof.
  • the compound represented by the formula (I), which is the active ingredient of the activity enhancer of the antifungal agent of one aspect of the present invention includes known or novel natural organic compounds glycoprenins and related compounds thereof. That is, the compound represented by the formula (I) includes the compound represented by the formula (Ia). Therefore, the compound represented by the formula (I), which is the active ingredient of the activity enhancer of the antifungal agent of one aspect of the present invention, particularly the compound represented by the formula (Ia) of the one aspect of the present invention is antifungal.
  • the antifungal activity of fungal drugs can be effectively enhanced.
  • the compound represented by the formula (Ia) is a novel compound not disclosed in the prior art.
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia) has a higher antifungal activity enhancing effect than the compounds described in, for example, Patent Documents 1 to 3.
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia) has a polyterpenoid skeleton.
  • Such a skeletal structure of the compound represented by the formula (I), particularly the compound represented by the formula (Ia) is, for example, an active ingredient contained in the activity enhancer of the antifungal drug described in Patent Documents 1 to 3. It differs from the skeletal structure of the compound.
  • the compound represented by the formula (I), which is the active ingredient of the activity enhancer of the antifungal agent of one aspect of the present invention, particularly the compound represented by the formula (Ia) of one aspect of the present invention has been conventionally used. There is a possibility that a significant therapeutic effect can be exhibited in patients who cannot obtain a sufficient antifungal activity enhancing effect with the above drugs.
  • R 1 ' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted Cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted heterocycloalkylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted.
  • Substituted arylalkyls substituted or unsubstituted heteroaryls, substituted or unsubstituted heteroarylalkyls, substituted or unsubstituted alkoxycarbonyls, substituted or unsubstituted cycloalkoxycarbonyls, or substituted or unsubstituted acyls.
  • R 1 ' is hydrogen, substituted or unsubstituted C 1 ⁇ C 6 alkyl, substituted or unsubstituted C 2 ⁇ C 6 alkenyl, substituted or unsubstituted C 2 ⁇ C 6 alkynyl, substituted or unsubstituted C 3 ⁇ C 6 cycloalkyl, substituted or unsubstituted C 3 to C 6 cycloalkenyl, substituted or unsubstituted C 3 to C 6 cycloalkynyl, substituted or unsubstituted 3- to 6-membered heterocycloalkyl, substituted or unsubstituted.
  • C 7 to C 11 cycloalkylalkyls substituted or unsubstituted 3- to 6-membered heterocycloalkyls-C 1 to C 6 alkyls, substituted or unsubstituted C 6 to C 18 aryls, substituted or unsubstituted C 7 ⁇ C 20 arylalkyl, substituted or unsubstituted 5-15 membered heteroaryl, substituted or unsubstituted 5-15 membered heteroaryl-C 1 to C 6 alkyl, substituted or unsubstituted C 1 to C 6 alkoxy
  • carbonyl substituted or unsubstituted C 3 to C 6 cycloalkoxycarbonyl, or substituted or unsubstituted C 1 to C 20 acyl; hydrogen, substituted or unsubstituted C 1 to C 6 alkyl, substituted or Unsubstituted C 2 to C 6 alkenyl, substituted or unsubstituted C 2 to C 6 alken
  • R 1 ' is a groups exemplified above, the compound represented by the formula (I), particularly compounds represented by Formula (Ia), it can be effectively enhanced antifungal activity of antifungal drugs it can.
  • R 6 and R 7 are independent of each other, hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkoxy, substituted or unsubstituted heterocycloalkoxy, substituted or Unsubstituted aryloxy, substituted or unsubstituted arylalkyloxy, substituted or unsubstituted arylalkoxyoxy, substituted or unsubstituted heteroaryloxy, substituted or unsubstituted heteroarylalkyloxy, or substituted or unsubstituted acyloxy Or R 6 and R 7 together form a covalent bond.
  • R 6 and R 7 are independent of each other, hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, substituted or unsubstituted C 3 to C 6 cycloalkoxy, substituted or unsubstituted 3 to 6 member hetero.
  • Cycloalkoxy substituted or unsubstituted C 6 to C 18 aryloxy, substituted or unsubstituted C 7 to C 20 arylalkyloxy, substituted or unsubstituted C 7 to C 20 arylalkoxyoxy, substituted or unsubstituted 5 ⁇ 15-membered heteroaryloxy, substituted or unsubstituted 5--15-membered heteroaryl-C 1 -C 6 alkyloxy, or substituted or unsubstituted C 1 -C 20 acyloxy, or R 6 and R 7 preferably form covalent bonds together; independently of each other, hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, or substituted or unsubstituted C 3 to C 6 cycloalkoxy.
  • R 6 and R 7 are more preferably combined to form a co-bond; either are hydroxyl, or R 6 and R 7 may be combined to form a co-bond. More preferably; they are particularly preferred to form covalent bonds together.
  • R 6 and R 7 are the groups exemplified above, the compound represented by the formula (I), particularly the compound represented by the formula (Ia), effectively enhances the antifungal activity of the antifungal drug. be able to.
  • R 10 and R 11 are independent of each other, hydrogen, hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkoxy, substituted or unsubstituted heterocycloalkoxy, substituted or unsubstituted.
  • R 10 and R 11 together form a covalent bond or -O-.
  • R 10 and R 11 are independent of each other, hydrogen, hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, substituted or unsubstituted C 3 to C 6 cycloalkoxy, substituted or unsubstituted 3 to 6 members. Heterocycloalkoxy, substituted or unsubstituted C 6 to C 18 aryloxy, substituted or unsubstituted C 7 to C 20 arylalkyloxy, substituted or unsubstituted C 7 to C 20 arylalkoxyoxy, substituted or unsubstituted.
  • R 10 and R 11 preferably together to form a covalent bond or -O-; independent of each other, hydrogen, hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, or substituted or unsubstituted C. It is more preferably 3 to C 6 cycloalkoxy, or R 10 and R 11 together to form a covalent bond or -O-; R 10 is hydrogen and R 11 is hydroxyl.
  • R 10 and R 11 are more preferably combined to form a covalent bond or -O-.
  • R 10 and R 11 are the groups exemplified above, the compound represented by the formula (I) can effectively enhance the antifungal activity of the antifungal agent.
  • R 10a is hydrogen
  • R 11a is hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkoxy, substituted or unsubstituted heterocycloalkoxy, substituted or unsubstituted.
  • aryloxy, substituted or unsubstituted arylalkyloxy, substituted or unsubstituted arylalkoxyoxy, substituted or unsubstituted heteroaryloxy, substituted or unsubstituted heteroarylalkyloxy, or substituted or unsubstituted acyloxy Or R 10a and R 11a together to form a covalent bond.
  • R 10a is hydrogen, and R 11a is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, substituted or unsubstituted C 3 to C 6 cycloalkoxy, substituted or unsubstituted 3 to 6 members.
  • Heterocycloalkoxy substituted or unsubstituted C 6 to C 18 aryloxy, substituted or unsubstituted C 7 to C 20 arylalkyloxy, substituted or unsubstituted C 7 to C 20 arylalkoxyoxy, substituted or unsubstituted 5 to 15 membered heteroaryloxy, substituted or unsubstituted 5 to 15 membered heteroaryl-C 1 to C 6 alkyloxy, or substituted or unsubstituted C 1 to C 20 acyloxy, or R 10a and R 11a preferably together to form a covalent bond; R 10a is hydrogen and R 11a is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, or substituted or unsubstituted.
  • R 10a and R 11a are more preferably combined to form a covalent bond.
  • R 10a and R 11a are the groups exemplified above, the compound represented by the formula (Ia) can effectively enhance the antifungal activity of the antifungal agent.
  • R 14 is hydrogen and R 15 is hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkoxy, substituted or unsubstituted heterocycloalkoxy, substituted or unsubstituted.
  • R 15 is hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkoxy, substituted or unsubstituted heterocycloalkoxy, substituted or unsubstituted.
  • R 14 is hydrogen, and R 15 is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, substituted or unsubstituted C 3 to C 6 cycloalkoxy, substituted or unsubstituted 3 to 6 members.
  • Heterocycloalkoxy substituted or unsubstituted C 6 to C 18 aryloxy, substituted or unsubstituted C 7 to C 20 arylalkyloxy, substituted or unsubstituted C 7 to C 20 arylalkoxyoxy, substituted or unsubstituted 5 to 15 membered heteroaryloxy, substituted or unsubstituted 5 to 15 membered heteroaryl-C 1 to C 6 alkyloxy, or substituted or unsubstituted C 1 to C 20 acyloxy, or R 14 and R 15 is preferably combined to form a covalent bond; R 14 is hydrogen and R 15 is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, or substituted or unsubstituted.
  • R 14 and R 15 are more preferably combined to form a covalent bond.
  • R 14 and R 15 are the groups exemplified above, the compound represented by the formula (I) can effectively enhance the antifungal activity of the antifungal agent.
  • R 14a is hydrogen
  • R 15a is hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkoxy, substituted or unsubstituted heterocycloalkoxy, substituted or unsubstituted.
  • R 14a is hydrogen, and R 15a is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, substituted or unsubstituted C 3 to C 6 cycloalkoxy, substituted or unsubstituted 3 to 6 members.
  • Heterocycloalkoxy substituted or unsubstituted C 6 to C 18 aryloxy, substituted or unsubstituted C 7 to C 20 arylalkyloxy, substituted or unsubstituted C 7 to C 20 arylalkoxyoxy, substituted or unsubstituted
  • R 14a Is hydrogen
  • R 15a is more preferably hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, or substituted or unsubstituted C 3 to C 6 cycloalkoxy
  • R 14a is hydrogen.
  • R 15a is more preferably hydroxyl.
  • R 19' , R 23' , and R 27' are independent of each other, hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted.
  • R 19 ', R 23', and R 27 ' are independently of one another, hydrogen, substituted or unsubstituted C 1 ⁇ C 6 alkyl, substituted or unsubstituted C 2 ⁇ C 6 alkenyl, substituted or unsubstituted C 2 to C 6 alkynyl, substituted or unsubstituted C 3 to C 6 cycloalkyl, substituted or unsubstituted C 3 to C 6 cycloalkenyl, substituted or unsubstituted C 3 to C 6 cycloalkynyl, substituted or unsubstituted 3- to 6-membered heterocycloalkyl, substituted or unsubstituted C 7 to C 11 cycloalkyl alkyl, substituted or unsubstituted 3- to 6-membered heterocycloalkyl-C 1 to C 6 alkyl, substituted or unsubstituted C 6 to C 18 aryl, substituted or unsubstituted C 7 to
  • R 31 , R 34 and R 35 are independently hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkoxy, substituted or unsubstituted.
  • R 31 , R 34 and R 35 are hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, substituted or unsubstituted C 3 to C 6 cycloalkoxy, substituted or unsubstituted, independently of each other.
  • Unsubstituted 3- to 6-membered heterocycloalkoxy substituted or unsubstituted C 6 to C 18 aryloxy, substituted or unsubstituted C 7 to C 20 arylalkyloxy, substituted or unsubstituted C 7 to C 20 aryl Alkoxyoxy, substituted or unsubstituted 5- to 15-membered heteroaryloxy, substituted or unsubstituted 5- to 15-membered heteroaryl-C 1 to C 6 alkyloxy, or substituted or unsubstituted C 1 to C 20 acyloxy.
  • it is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, or substituted or unsubstituted C 3 to C 6 cycloalkoxy independently of each other; both are hydroxyl. Is even more preferable.
  • R 31 and R 34 together form -O-, and R 35 is a hydroxyl, substituted or unsubstituted alkoxy.
  • R 35 is a hydroxyl, substituted or unsubstituted alkoxy.
  • substituted or unsubstituted heteroarylalkyloxy substituted or unsubstituted acyloxy.
  • R 31 and R 34 together form -O-, and R 35 is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, substituted or unsubstituted C 3 ⁇ C 6 cycloalkoxy, substituted or unsubstituted 3- to 6-membered heterocycloalkoxy, substituted or unsubstituted C 6 to C 18 aryloxy, substituted or unsubstituted C 7 to C 20 arylalkyloxy, substituted or unsubstituted.
  • Substituted C 7 to C 20 arylalkoxyoxy substituted or unsubstituted 5 to 15-membered heteroaryloxy, substituted or unsubstituted 5 to 15-membered heteroaryl-C 1 to C 6 alkyloxy, or substituted or non-substituted Preferred are substituted C 1 to C 20 acyloxys; R 31 and R 34 together form -O-, and R 35 is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy. , Or substituted or unsubstituted C 3 to C 6 cycloalkoxy; R 31 and R 34 together form -O-, and R 35 is further preferred to be hydroxyl. preferable.
  • R 31 is hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkoxy, substituted or unsubstituted heterocycloalkoxy, substituted.
  • R 31 is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, substituted or unsubstituted C 3 to C 6 cycloalkoxy, substituted or unsubstituted 3- to 6-membered heterocycloalkoxy.
  • R 31 , R 34 and R 35 are the groups exemplified above, the compound represented by the formula (I) can effectively enhance the antifungal activity of the antifungal agent.
  • R 31a , R 34a and R 35a are independently hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkoxy, substituted or non-substituted.
  • R 31a , R 34a and R 35a are hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, substituted or unsubstituted C 3 to C 6 cycloalkoxy, substituted or substituted independently of each other.
  • Unsubstituted 3- to 6-membered heterocycloalkoxy substituted or unsubstituted C 6 to C 18 aryloxy, substituted or unsubstituted C 7 to C 20 arylalkyloxy, substituted or unsubstituted C 7 to C 20 aryl Alkoxyoxy, substituted or unsubstituted 5- to 15-membered heteroaryloxy, substituted or unsubstituted 5- to 15-membered heteroaryl-C 1 to C 6 alkyloxy, or substituted or unsubstituted C 1 to C 20 acyloxy.
  • R 10a and R 11a form a covalent bond together, none of R 31a , R 34a and R 35a is a hydroxyl group.
  • R 31a and R 34a together form -O-, and R 35a is a hydroxyl, substituted or unsubstituted alkoxy.
  • R 35a is a hydroxyl, substituted or unsubstituted alkoxy.
  • substituted or unsubstituted heteroarylalkyloxy substituted or unsubstituted acyloxy.
  • R 31a and R 34a together form -O-
  • R 35a is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, substituted or unsubstituted C 3 ⁇ C 6 cycloalkoxy, substituted or unsubstituted 3- to 6-membered heterocycloalkoxy, substituted or unsubstituted C 6 to C 18 aryloxy, substituted or unsubstituted C 7 to C 20 arylalkyloxy, substituted or unsubstituted.
  • Substituted C 7 to C 20 arylalkoxyoxy substituted or unsubstituted 5 to 15-membered heteroaryloxy, substituted or unsubstituted 5 to 15-membered heteroaryl-C 1 to C 6 alkyloxy, or substituted or non-substituted It is preferably substituted C 1 to C 20 acyloxy; R 31a and R 34a together form -O-, and R 35a is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy. , Or substituted or unsubstituted C 3 to C 6 cycloalkoxy; R 31a and R 34a together form -O-, and R 35a is further hydroxylated. preferable.
  • R 31a is hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkoxy, substituted or unsubstituted heterocycloalkoxy, substituted.
  • R 31a is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, substituted or unsubstituted C 3 to C 6 cycloalkoxy, substituted or unsubstituted 3- to 6-membered heterocycloalkoxy.
  • R 31a and R 34a together form -O-, and R 35a is a hydroxyl group.
  • R 31a , R 34a and R 35a are the groups exemplified above, the compound represented by the formula (Ia) can effectively enhance the antifungal activity of the antifungal agent.
  • the substituents are independently halogen (fluorine, chlorine, bromine or iodine), cyano, nitro, hydroxyl, substituted or unsubstituted.
  • Substituted C 1 to C 6 alkyl substituted or unsubstituted C 2 to C 6 alkenyl, substituted or unsubstituted C 2 to C 6 alkynyl, substituted or unsubstituted C 3 to C 6 cycloalkyl, substituted or unsubstituted.
  • C 4 to C 6 cycloalkenyl substituted or unsubstituted C 4 to C 6 cycloalkynyl, substituted or unsubstituted 3 to 6-membered heterocycloalkyl, substituted or unsubstituted C 7 to C 11 cycloalkylalkyl, Substituted or unsubstituted 3- to 6-membered heterocycloalkyl-C 1 to C 6 alkyl, substituted or unsubstituted C 6 to C 18 aryl, substituted or unsubstituted C 7 to C 20 aryl alkyl, substituted or unsubstituted.
  • the monovalent group or divalent group is preferably unsubstituted.
  • the substituent is preferably further selected from the monovalent or divalent group and further from the unsubstituted monovalent or divalent group. More preferably selected.
  • the compounds represented by the formula (I) are R 1' , R 6 , R 7 , R 10 , R 11 , R 14 , R 15 , R 19' , R 23' , R 27' , exemplified above. Compounds defined by any combination of R 31 , R 34 and R 35 can be included.
  • R 31a , R 34a and R 35a can include compounds defined by any combination.
  • the compound represented by the formula (I) is R 1 'is hydrogen, substituted or unsubstituted C 1 ⁇ C 6 alkyl, substituted or unsubstituted C 2 ⁇ C 6 alkenyl, substituted or unsubstituted C 2 ⁇ C 6 alkynyl, substituted or unsubstituted C 3 ⁇ C 6 cycloalkyl, substituted or unsubstituted C 3 to C 6 cycloalkenyl, substituted or unsubstituted C 3 to C 6 cycloalkynyl, substituted or unsubstituted 3- to 6-membered heterocycloalkyl, substituted or unsubstituted.
  • C 7 to C 11 cycloalkylalkyl, substituted or unsubstituted 3- to 6-membered heterocycloalkyl-C 1 to C 6 alkyl, substituted or unsubstituted C 6 to C 18 aryl, substituted or unsubstituted C 7 ⁇ C 20 arylalkyl, substituted or unsubstituted 5-15 membered heteroaryl, substituted or unsubstituted 5-15 membered heteroaryl-C 1 to C 6 alkyl, substituted or unsubstituted C 1 to C 6 alkoxy Carbonyl, substituted or unsubstituted C 3 to C 6 cycloalkoxycarbonyl, or substituted or unsubstituted C 1 to C 20 acyl;
  • R 6 and R 7 are independent of each other, hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, substituted or unsubstituted C 3 to C 6 cycloalkoxy, substituted or
  • Cycloalkoxy substituted or unsubstituted C 6 to C 18 aryloxy, substituted or unsubstituted C 7 to C 20 arylalkyloxy, substituted or unsubstituted C 7 to C 20 arylalkoxyoxy, substituted or unsubstituted 5 ⁇ 15-membered heteroaryloxy, substituted or unsubstituted 5--15-membered heteroaryl-C 1 -C 6 alkyloxy, or substituted or unsubstituted C 1 -C 20 acyloxy, or R 6 and R 7 together form a covalent bond;
  • R 10 and R 11 are independent of each other, hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, substituted or unsubstituted C 3 to C 6 cycloalkoxy, substituted or unsubstituted 3- to 6-membered hetero.
  • Cycloalkoxy substituted or unsubstituted C 6 to C 18 aryloxy, substituted or unsubstituted C 7 to C 20 arylalkyloxy, substituted or unsubstituted C 7 to C 20 arylalkoxyoxy, substituted or unsubstituted 5 ⁇ 15-membered heteroaryloxy, substituted or unsubstituted 5--15-membered heteroaryl-C 1 -C 6 alkyloxy, or substituted or unsubstituted C 1 -C 20 acyloxy, or R 10 and R 11 together form a covalent bond or -O-;
  • R 14 is hydrogen, and R 15 is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, substituted or unsubstituted C 3 to C 6 cycloalkoxy, substituted or unsubstituted 3 to 6 members.
  • R 19 ', R 23', and R 27 ' are independently of one another, hydrogen, substituted or unsubstituted C 1 ⁇ C 6 alkyl, substituted or unsubstituted C 2 ⁇ C 6 alkenyl, substituted or unsubstituted C 2 to C 6 alkynyl, substituted or unsubstituted C 3 to C 6 cyclo
  • Substituted 5- to 15-membered heteroaryloxy substituted or unsubstituted 5- to 15-membered heteroaryl-C 1 to C 6 alkyloxy, or substituted or unsubstituted C 1 to C 20 acyloxy, or R. 31 and R 34 together form -O-, and R 35 is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, substituted or unsubstituted C 3 to C 6 cycloalkoxy, substituted.
  • unsubstituted 3- to 6-membered heterocycloalkoxy substituted or unsubstituted C 6 to C 18 aryloxy, substituted or unsubstituted C 7 to C 20 arylalkyloxy, substituted or unsubstituted C 7 to C 20.
  • Aryloxy or R 31 is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, substituted or unsubstituted C 3 to C 6 cycloalkoxy, substituted or unsubstituted 3- to 6-membered heterocycloalkoxy.
  • the substituents are independently halogen (fluorine, chlorine, bromine or iodine), cyano, nitro, hydroxyl, substituted or unsubstituted C 1 to C 6 alkyl, substituted or Unsubstituted C 2 to C 6 alkoxys, substituted or unsubstituted C 2 to C 6 alkoxyls, substituted or unsubstitute
  • Substituted 5- to 15-membered heteroaryl-C 1 to C 6 alkyloxy, substituted or unsubstituted C 1 to C 6 alkoxycarbonyl, substituted or unsubstituted C 3 to C 6 cycloalkoxycarbonyl, substituted or unsubstituted At least one monovalent or divalent group selected from the group consisting of C 1 to C 20 acyls, substituted or unsubstituted C 1 to C 20 acyloxys, substituted or unsubstituted aminos, and oxo (C O). It is the basis.
  • the monovalent group or divalent group is preferably unsubstituted.
  • the substituent is preferably further selected from the monovalent or divalent group and further from the unsubstituted monovalent or divalent group. More preferably selected.
  • the compound represented by the formula (I) is R 1 'is hydrogen, substituted or unsubstituted C 1 ⁇ C 6 alkyl, substituted or unsubstituted C 2 ⁇ C 6 alkenyl, substituted or unsubstituted C 2 ⁇ C 6 alkynyl, substituted or unsubstituted C 3 ⁇ C 6 cycloalkyl, substituted or unsubstituted C 4 to C 6 cycloalkenyl, or substituted or unsubstituted C 4 to C 6 cycloalkynyl; R 6 and R 7 are independently hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, or substituted or unsubstituted C 3 to C 6 cycloalkoxy, or R 6 and R 7 are Together to form a covalent bond; R 10 and R 11 are independent of each other, hydrogen, hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, or substituted or
  • R 14 is hydrogen and R 15 is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, or substituted or unsubstituted C 3 to C 6 cycloalkoxy, or R 14 and R 15 Together to form a covalent bond;
  • R 19 ', R 23', and R 27 ' are independently of one another, hydrogen, substituted or unsubstituted C 1 ⁇ C 6 alkyl, substituted or unsubstituted C 2 ⁇ C 6 alkenyl, substituted or unsubstituted C 2 to C 6 alkynyl, substituted or unsubstituted C 3 to C 6 cycloalkyl, substituted or unsubstituted C 3 to C 6 cycloalkenyl, or substituted or unsubstituted C 3 to C 6 cycloalkynyl;
  • R 31 , R 34 and R 35 are independently hydroxyl, substituted or unsubstituted C 1
  • R 31 is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, or substituted or unsubstituted C 3 to C 6 cycloalkoxy, and R 34 and R 35 are covalently bonded together.
  • the substituent is halogen (fluorine, chlorine, bromine or iodine), cyano, nitro, hydroxyl, substituted or unsubstituted C 1 to C 6 alkyl, substituted or unsubstituted C 2 ⁇ C 6 Alkoxy, substituted or unsubstituted C 2 to C 6 alkoxyyl, substituted or unsubstituted C 3 to C 6 cycloalkyl, substituted or unsubstituted C 4 to C 6 cycloalkoxy, substituted or unsubstituted C 4 ⁇ C 6 cycloalkoxyyl, substituted or unsubstituted 3- to 6-membered heterocycloalkyl, substituted or unsubstituted C 7 to C 11 cycloalkylalkyl, substituted or unsubstituted 3- to 6-membered heterocycloalkyl-C 1 ⁇ C 6 Alkoxy, substituted or unsubstituted C 6
  • the monovalent group or divalent group is preferably unsubstituted.
  • the substituent is preferably further selected from the monovalent or divalent group and further from the unsubstituted monovalent or divalent group. More preferably selected.
  • the compound represented by the formula (I) is R 1 'is hydrogen, methyl, ethyl, propyl, butyl, pentyl or hexyl; R 6 and R 7 are both hydroxyl groups, or R 6 and R 7 together form a covalent bond; R 10 is hydrogen and R 11 is hydroxyl, or R 10 and R 11 together form a covalent bond or -O-; R 14 is hydrogen and R 15 is a hydroxyl, or R 14 and R 15 together form a covalent bond; R 19 ', R 23', and R 27 'independently of one another are hydrogen, methyl, ethyl, propyl, butyl, pentyl or hexyl; R 31 , R 34 and R 35 are all hydroxyl groups, or R 31 and R 34 together form -O-, and R 35 is a hydroxyl group, or R 31 is , Hydroxy, and R 34 and R 35 together form a covalent bond.
  • the compound represented by the formula (I) is R 1'is hydrogen; R 6 and R 7 are both hydroxyl groups, or R 6 and R 7 together form a covalent bond; R 10 is hydrogen and R 11 is hydroxyl, or R 10 and R 11 together form a covalent bond or -O-; R 14 is hydrogen and R 15 is a hydroxyl, or R 14 and R 15 together form a covalent bond; R 19' , R 23' , and R 27'are all hydrogen; R 31 , R 34 and R 35 are all hydroxyl groups, or R 31 and R 34 together form -O-, and R 35 is a hydroxyl group, or R 31 is , Hydroxy, and R 34 and R 35 together form a covalent bond.
  • the compound represented by the formula (Ia) is R 1 'is hydrogen, substituted or unsubstituted C 1 ⁇ C 6 alkyl, substituted or unsubstituted C 2 ⁇ C 6 alkenyl, substituted or unsubstituted C 2 ⁇ C 6 alkynyl, substituted or unsubstituted C 3 ⁇ C 6 cycloalkyl, substituted or unsubstituted C 3 to C 6 cycloalkenyl, substituted or unsubstituted C 3 to C 6 cycloalkynyl, substituted or unsubstituted 3- to 6-membered heterocycloalkyl, substituted or unsubstituted.
  • C 7 to C 11 cycloalkylalkyl, substituted or unsubstituted 3- to 6-membered heterocycloalkyl-C 1 to C 6 alkyl, substituted or unsubstituted C 6 to C 18 aryl, substituted or unsubstituted C 7 ⁇ C 20 arylalkyl, substituted or unsubstituted 5-15 membered heteroaryl, substituted or unsubstituted 5-15 membered heteroaryl-C 1 to C 6 alkyl, substituted or unsubstituted C 1 to C 6 alkoxy Carbonyl, substituted or unsubstituted C 3 to C 6 cycloalkoxycarbonyl, or substituted or unsubstituted C 1 to C 20 acyl;
  • R 6 and R 7 are independent of each other, hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, substituted or unsubstituted C 3 to C 6 cycloalkoxy, substituted or
  • R 10a is hydrogen, and R 11a is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, substituted or unsubstituted C 3 to C 6 cycloalkoxy, substituted or unsubstituted 3 to 6 members.
  • Heterocycloalkoxy substituted or unsubstituted C 6 to C 18 aryloxy, substituted or unsubstituted C 7 to C 20 arylalkyloxy, substituted or unsubstituted C 7 to C 20 arylalkoxyoxy, substituted or unsubstituted 5 to 15 membered heteroaryloxy, substituted or unsubstituted 5 to 15 membered heteroaryl-C 1 to C 6 alkyloxy, or substituted or unsubstituted C 1 to C 20 acyloxy, or R 10a and R 11a together form a covalent bond;
  • R 14a is hydrogen;
  • R 15a is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, substituted or unsubstituted C 3 to C 6 cycloalkoxy, substituted or unsubstituted 3 to 6 member heterocycloalkoxy, substituted or unsubstituted.
  • R 19 ', R 23', and R 27 ' are independently of one another, hydrogen, substituted or unsubstituted C 1 ⁇ C 6 alkyl, substituted or unsubstituted C 2 ⁇ C 6 alkenyl, substituted or unsubstituted C 2 to C 6 alkynyl, substituted or unsubstituted C 3 to C 6 cycloalkyl, substituted or unsubstituted C 3 to C 6 cycloalkenyl, substituted or
  • heterocycloalkoxy substituted or unsubstituted C 6 to C 18 aryloxy, substituted or unsubstituted C 7 to C 20 arylalkyloxy, substituted or unsubstituted C 7 to C 20 arylalkenyloxy, substituted or unsubstituted.
  • substituted 5- to 15-membered heteroaryloxy a substituted or unsubstituted 5- to 15-membered heteroaryl-C 1 to C 6 alkyloxy, or a substituted or unsubstituted C 1 to C 20 acyloxy (provided that it is)?
  • R 10a and R 11a together form a covalent bond, then neither R 31a , R 34a, nor R 35a is hydroxyl), or R 31a and R 34a together- O- is formed and R 35a is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, substituted or unsubstituted C 3 to C 6 cycloalkoxy, substituted or unsubstituted 3- to 6-membered heterocyclo.
  • the substituents are independently halogen (fluorine, chlorine, bromine or iodine), cyano, nitro, hydroxyl, substituted or unsubstituted C 1 to C 6 alkyl, substituted or Unsubstituted C 2 to C 6 alkoxys, substituted or unsubstituted C 2 to C 6 alkoxyls, substituted or unsubstituted C 3 to C 6 cycloalkyls, substituted or unsubstituted C 4 to C 6 cycloalkoxys, substituted or Unsubstituted C 4 to C 6 cycloalkoxyyl, substituted or unsubstituted 3- to 6-membered heterocycloalkyl, substituted or unsubstituted C 7 to C 11 cycloalkylalkyl, substituted or unsubstituted 3- to 6-membered hetero Cycloalkyl-C 1 to C 6 alkyl, substituted or unsubstituted C 1 to C 6 alkyl
  • Substituted 5- to 15-membered heteroaryl-C 1 to C 6 alkyloxy, substituted or unsubstituted C 1 to C 6 alkoxycarbonyl, substituted or unsubstituted C 3 to C 6 cycloalkoxycarbonyl, substituted or unsubstituted At least one monovalent or divalent group selected from the group consisting of C 1 to C 20 acyls, substituted or unsubstituted C 1 to C 20 acyloxys, substituted or unsubstituted aminos, and oxo (C O). It is the basis.
  • the monovalent group or divalent group is preferably unsubstituted.
  • the substituent is preferably further selected from the monovalent or divalent group and further from the unsubstituted monovalent or divalent group. More preferably selected.
  • the compound represented by the formula (Ia) is R 1 'is hydrogen, substituted or unsubstituted C 1 ⁇ C 6 alkyl, substituted or unsubstituted C 2 ⁇ C 6 alkenyl, substituted or unsubstituted C 2 ⁇ C 6 alkynyl, substituted or unsubstituted C 3 ⁇ C 6 cycloalkyl, substituted or unsubstituted C 4 to C 6 cycloalkenyl, or substituted or unsubstituted C 4 to C 6 cycloalkynyl; R 6 and R 7 are independently hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, or substituted or unsubstituted C 3 to C 6 cycloalkoxy, or R 6 and R 7 are Together to form a covalent bond; R 10a is hydrogen and R 11a is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, or substituted or unsub
  • R 14a is hydrogen;
  • R 15a is hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, or substituted or unsubstituted C 3 to C 6 cycloalkoxy;
  • R 19 ', R 23', and R 27 ' are independently of one another, hydrogen, substituted or unsubstituted C 1 ⁇ C 6 alkyl, substituted or unsubstituted C 2 ⁇ C 6 alkenyl, substituted or unsubstituted C 2 to C 6 alkynyl, substituted or unsubstituted C 3 to C 6 cycloalkyl, substituted or unsubstituted C 3 to C 6 cycloalkenyl, or substituted or unsubstituted C 3 to C 6 cycloalkynyl;
  • R 31a , R 34a and R 35a are hydroxyl, substituted or unsubstituted C 1 to C 6 alkoxy, or substituted or unsubsti
  • Substituted C 1 to C 6 alkoxy, or substituted or unsubstituted C 3 to C 6 cycloalkoxy, and R 34a and R 35a together form a covalent bond;
  • the substituent is halogen (fluorine, chlorine, bromine or iodine), cyano, nitro, hydroxyl, substituted or unsubstituted C 1 to C 6 alkyl, substituted or unsubstituted C 2 ⁇ C 6 Alkoxy, substituted or unsubstituted C 2 to C 6 alkoxyyl, substituted or unsubstituted C 3 to C 6 cycloalkyl, substituted or unsubstituted C 4 to C 6 cycloalkoxy, substituted or unsubstituted C 4 ⁇ C 6 cycloalkoxyyl, substituted or unsubstituted 3- to 6-membered heterocycloalkyl, substituted or unsubstituted C 7 to C 11 cyclo
  • the monovalent group or divalent group is preferably unsubstituted.
  • the substituent is preferably further selected from the monovalent or divalent group and further from the unsubstituted monovalent or divalent group. More preferably selected.
  • the compound represented by the formula (Ia) is R 1 'is hydrogen, methyl, ethyl, propyl, butyl, pentyl or hexyl; R 6 and R 7 are both hydroxyl groups, or R 6 and R 7 together form a covalent bond; R 10a is hydrogen and R 11a is a hydroxyl, or R 10a and R 11a together form a covalent bond; R 14a is hydrogen; R 15a is a hydroxyl; R 19 ', R 23', and R 27 'independently of one another are hydrogen, methyl, ethyl, propyl, butyl, pentyl or hexyl; Are R 31a , R 34a and R 35a all hydroxyl (however, if R 10a and R 11a together form a covalent bond, then R 31a , R 34a and R 35a are all hydroxyl groups? (There is no such thing), or R 31a and R 34a together form -O-,
  • the compound represented by the formula (Ia) is R 1'is hydrogen; R 6 and R 7 together form a covalent bond; R 10a is hydrogen and R 11a is a hydroxyl, or R 10a and R 11a together form a covalent bond; R 14a is hydrogen; R 15a is a hydroxyl; R 19' , R 23' , and R 27'are all hydrogen; R 31a and R 34a together form -O-, and R 35a is a hydroxyl group.
  • Particularly preferable compounds represented by the formula (I) are as follows: (2E, 6E) -30-(5- (2-Hydroxypropan-2-yl) -2-methyltetra-2-yl) -3,7,11,15,19,23,27-Heptamethyltriacone -2,6-diene-1,11,15,19,23,27-hexaol (Compound 1; glycoprenin G); (2E, 6E, 10E) -30-(5- (2-Hydroxypropan-2-yl) -2-methyltetra-2-yl) -3,7,11,15,19,23,27-Heptamethyl Triaconta-2,6,10-triene-1,15,19,23,27-pentaol (Compound 2; glycoprenin H); and (2E, 6E, 10E) -3,7,11,15,19, 23,27,31,35-Nonamethylhexatriaconta-2,6,
  • Particularly preferred compounds represented by the formula (Ia) are: (2E, 6E) -30-(5- (2-Hydroxypropan-2-yl) -2-methyltetra-2-yl) -3,7,11,15,19,23,27-Heptamethyltriacone -2,6-diene-1,11,15,19,23,27-Hexaol (Compound 1; Glysoprenin G); and (2E, 6E, 10E) -30-(5- (2-Hydroxypropane-2) -Il) -2-methyltetra-2-yl) -3,7,11,15,19,23,27-Heptamethyltriaconta-2,6,10-Triene-1,15,19,23,27 -Pentaol (Compound 2; Glysoprenin H); Is.
  • the compound represented by the formula (I) which is the active ingredient of the activity enhancer of the antifungal agent of the present invention, particularly the compound represented by the formula (Ia) of the present invention is the compound.
  • the compound can particularly effectively enhance the antifungal activity of the antifungal agent.
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia), includes not only the compound itself but also a salt thereof.
  • the salt of the compound represented by the formula (I), particularly the compound represented by the formula (Ia), is not limited, but is, for example, sodium ion, potassium ion, calcium ion, magnesium ion, or substituted or non-substituted. Salts with cations such as substituted ammonium ions, or inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitrate, carbonic acid or phosphoric acid, or formic acid, acetic acid, maleic acid, fumaric acid, benzoic acid, ascorbic acid.
  • Succinic acid bismethylene salicylic acid, methanesulfonic acid, ethanedisulfonic acid, propionic acid, tartaric acid, salicylic acid, citric acid, gluconic acid, aspartic acid, stearic acid, palmitic acid, itaconic acid, glycolic acid, p-aminobenzoic acid, Salts with organic acid anions such as glutamic acid, benzenesulfonic acid, cyclohexylsulfamic acid, methanesulfonic acid, ethanesulfonic acid, isethionic acid, p-toluenesulfonic acid or naphthalenesulfonic acid are preferred. Even when the compound represented by the formula (I), particularly the compound represented by the formula (Ia), is in the form of the salt, the antifungal activity of the antifungal drug can be effectively enhanced. ..
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia), includes not only the compound itself but also a solvate of the compound or a salt thereof.
  • the solvent that can form a solvent mixture with the compound or a salt thereof is not limited, but is, for example, water, or a lower alcohol (for example, methanol, ethanol or 2-propanol (isopropyl alcohol)). Alcohols with up to 6 carbon atoms), higher alcohols (eg alcohols with 7 or more carbon atoms such as 1-heptanol or 1-octanol), dimethylsulfoxide (DMSO), acetic acid, ethanolamine or ethyl acetate An organic solvent such as is preferred.
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia), includes not only the compound itself but also a protected form thereof.
  • protected form means a form in which a protecting group is introduced into one or more functional groups (for example, an amino group, a hydroxyl group or a carboxylic acid group).
  • the protected form of the compound represented by each of the above formulas may be described as a protected derivative of the compound represented by each of the above formulas.
  • the "protecting group” is a group introduced into a specific functional group in order to prevent the undesired progress of the reaction, and is quantitatively removed under the specific reaction conditions.
  • the protecting group that can form the protected form of the compound is not limited, but for example, in the case of an amino group protecting group, t-butoxycarbonyl (Boc), 2-bromobenzyloxycarbonyl (BrZ), or If 9-fluorenylmethoxycarbonyl (Fmoc) is a protecting group for the hydroxyl group, silyl (eg, t-butyldimethylsilyl (TBS), triisopropylsilyl (TIPS) or tert-butyldiphenylsilyl (TBDPS)), Alternatively, if the alkoxy (eg, methoxymethoxy (MOM) or methoxy (Me)) is a protecting group for a carboxylic acid group, an alkyl ester (eg, methyl, ethyl or isopropyl ester), an arylalky
  • an amide with oxazolidinones are preferable.
  • the protection and deprotection by the protecting group can be appropriately carried out by those skilled in the art based on known reaction conditions. Even when the compound represented by the formula (I), particularly the compound represented by the formula (Ia), is in the protected form by the protecting group, the activity enhancing effect of the antifungal drug is substantially reduced. In some cases, the compound can be used.
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia), has one or more tautomers
  • the compound is in the form of individual tautomers of the compound. Also includes.
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia) has one or a plurality of stereocenters (chiral centers), the compound is an individual enantiomer of the compound and It also includes diastereomers, as well as mixtures thereof such as racemates.
  • the compound represented by the formula (I) which is the active ingredient of the activity enhancer of the antifungal agent of one aspect of the present invention, particularly the compound represented by the formula (Ia) of one aspect of the present invention.
  • the compound can effectively enhance the antifungal activity of the antifungal agent.
  • the method of the present invention includes a compound accumulation step and a compound purification step.
  • a compound accumulation step and a compound purification step.
  • the method of the invention is a fungal Aspergillus polyporicola BFM-0088 strain (received) capable of producing a compound of formula (I), in particular a compound of formula (Ia).
  • a compound in which a microorganism represented by No. NITE ABP-02936) or a mutant strain thereof is cultured in a medium to accumulate a compound represented by the formula (I), particularly a compound represented by the formula (Ia) in the medium. Includes accumulation step.
  • Aspergillus polypolycola BFM-0088 strain is a fungus isolated from the soil of Tokyo Bay, Tokyo, Japan. This strain was released as BFM-0088 on April 3, 2019, at the National Institute of Technology and Evaluation Patent Microorganisms Depositary Center (2-5-8 Kazusakamatari, Kisarazu City, Chiba Prefecture, Japan 292-0818 122). Room No.) has been deposited internationally based on the Butapest Convention (receipt number NITE ABP-02936).
  • the microorganism used for culturing is Aspergillus polypolycola BFM-0088 strain or a mutant strain thereof having an ability to produce a compound represented by the formula (I), particularly a compound represented by the formula (Ia). It is preferably present, and more preferably the Aspergillus polypolycola BFM-0088 strain.
  • the mutant strain of Aspergillus polypolycola BFM-0088 strain means a natural mutant strain or an artificial mutant strain of Aspergillus polypolycola BFM-0088 strain.
  • the artificial mutant strain of Aspergillus polypolycola BFM-0088 strain can be obtained by any means for producing an artificial mutant strain commonly used in the art.
  • the Aspergillus polypolycola BFM-0088 strain itself, but also a mutant strain of the Aspergillus polypolycola BFM-0088 strain produces a compound represented by the formula (I), particularly a compound represented by the formula (Ia).
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia) can be accumulated in the medium in this step. Therefore, by using the microorganism, a large amount of the compound represented by the formula (I), particularly the compound represented by the formula (Ia) can be accumulated in the medium.
  • the medium used for culturing the microorganism can be appropriately selected based on the properties of the microorganism.
  • the medium usually contains one or more carbon sources and one or more nitrogen sources, and optionally one or more inorganic salts and one or more vitamins.
  • the carbon source include sugars such as glucose, fructose, maltose, lactose, galactose, dextrin and starch, and vegetable oils and fats such as soybean oil.
  • the nitrogen source include polypeptone, yeast extract, malt extract, meat extract, soybean flour, cottonseed flour, corn Steve liquor, casein, amino acids, urea, ammonium salts and nitrates.
  • Inorganic salts include cations such as sodium ion, potassium ion, calcium ion, magnesium ion, iron ion, manganese ion, copper ion, cobalt ion or zinc ion, and inorganic salts such as hydrochloric acid, sulfuric acid, nitric acid, carbonic acid or phosphoric acid. Salts with acid anions can be mentioned.
  • the media used in this step are, for example, potato / dextrose / agar (PDA) medium (potato / dextrose / agar 3.9% (Becton Dickinson (BD))) and seed medium (1.0% glucose (Fuji Film Wako Pure Chemical Co., Ltd.)).
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia) can be accumulated in the medium.
  • the culture of microorganisms may be either solid culture or liquid culture.
  • liquid culture is preferable.
  • the air introduced into the medium is preferably sterilized using a sterilization means such as a sterilization filter.
  • the microorganism When culturing the microorganism on a large scale, the microorganism is cultivated in a small amount of medium in advance (hereinafter, also referred to as “seed culture”), and then the culture obtained by the seed culture is planted in a large volume medium. It is preferable to cultivate the cells (hereinafter, also referred to as "production culture”).
  • the components of the medium used for the seed culture and the production culture may be the same or different.
  • the conditions for culturing the microorganism can be appropriately set based on the properties of the microorganism.
  • the culture temperature is usually in the range of 25-27 ° C, typically about 27 ° C.
  • the pH of the medium is usually pH 3-9, typically pH 5.6 ⁇ 0.2.
  • the total of seed culture and production culture is usually 1 day to 3 weeks, and typically 3 to 17 days.
  • the method of the present invention is a compound purification step of purifying a compound represented by the formula (I) obtained in the compound accumulation step, particularly a compound represented by the formula (Ia), from the culture of the microorganism. including.
  • a means for purifying the compound represented by the formula (I), particularly the compound represented by the formula (Ia), from the culture of microorganisms a method for separating organic compounds usually used in the art is used. Can be used.
  • Means for purifying a compound represented by the formula (I), particularly a compound represented by the formula (Ia), from a culture of microorganisms include, for example, extraction, filtration, centrifugation, adsorption, recrystallization, distillation, and various types. Chromatography and the like can be mentioned.
  • this step is a step of separating the bacterial cells from the culture of the microorganism obtained in the compound accumulation step by filtration, centrifugation or the like, a step of extracting the separated bacterial cells with an organic solvent such as ethanol or ethyl acetate, and the like. And a step of further separating the bacterial cell extract extracted with an organic solvent by means such as solvent extraction or preparative chromatography to obtain a compound represented by the formula (I), particularly a compound represented by the formula (Ia). including.
  • the preparative chromatography various chromatographies such as adsorption, normal phase or reverse phase partitioning, and gel filtration can be applied.
  • the fraction obtained by preparative chromatography may be further purified by means such as recrystallization or distillation.
  • Each of the above steps may be repeated a plurality of times under the same or different conditions, if desired.
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia) can be purified and isolated from the culture of the microorganism.
  • the compound represented by the formula (I) is the group R 1' , R 6 , R 7 , R 10 , R 11 , R 14 exemplified above.
  • R 15 , R 19' , R 23' , and R 27' , R 31 , R 34 and R 35 and in particular the compounds represented by formula (Ia) are the groups R 1 exemplified above. It is preferred to have ' , R 6 , R 7 , R 10a , R 11a , R 14a , R 15a , R 19' , R 23' , and R 27' , R 31a , R 34a and R 35a .
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia) includes glycoprenin G (Compound 1) and glycoprenin H (Compound 2) produced by the Aspergillus polypolycola BFM-0088 strain. To do.
  • a compound represented by the formula (I) including glycoprenin G (Compound 1) and glycoprenin H (Compound 2), particularly a compound represented by the formula (Ia) can be efficiently produced. can do.
  • a compound represented by the formula (I), particularly a compound represented by the formula (Ia), which can be an active ingredient of a drug is highly produced. It can be provided in large quantities with purity and low cost.
  • Another aspect of the present invention is the fungal Aspergillus polypolycola BFM-0088 strain (receipt number NITE ABP-02936) capable of producing a compound represented by the formula (I), particularly a compound represented by the formula (Ia). ) Or a microorganism that is a mutant strain thereof.
  • the compounds represented by the formula (I) are the groups R 1' , R 6 , R 7 , R 10 , R 11 , R 14 , R 15 , R 19' , R 23' , exemplified above.
  • R 27' , R 31 , R 34 and R 35 and in particular the compounds represented by formula (Ia) are the groups R 1' , R 6 , R 7 , R 10a , R exemplified above. It is preferred to have 11a , R 14a , R 15a , R 19' , R 23' , and R 27' , R 31a , R 34a and R 35a .
  • a compound represented by the formula (I) including glycoprenin G (Compound 1) and glycoprenin H (Compound 2) particularly a compound represented by the formula (Ia) can be efficiently produced. can do.
  • the compound represented by the formula (I), which is the active ingredient of the activity enhancer of the antifungal agent of one aspect of the present invention, particularly the compound represented by the formula (Ia) of the one aspect of the present invention is the antifungal agent. It has an activity to enhance antifungal activity. Therefore, another aspect of the present invention is a compound represented by the formula (I), particularly a compound represented by the formula (Ia) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvent thereof.
  • the present invention relates to an activity enhancer of at least one antifungal drug containing a Japanese compound as an active ingredient.
  • a compound represented by the formula (I), particularly a compound represented by the formula (Ia) is administered to a subject, a specific symptom, disease or a specific symptom, disease or Disorders can be prevented or treated. Therefore, another aspect of the present invention is a compound represented by the formula (I), particularly a compound represented by the formula (Ia) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvent thereof.
  • the present invention relates to a drug or a pharmaceutical composition containing a Japanese product as an active ingredient.
  • At least one antifungal agent is selected from the group consisting of polyene macrolide agents, azole agents, canin agents and fluoropyrimidine agents.
  • the at least one antifungal agent is preferably a polyene macrolide agent.
  • the polyene macrolide drug is preferably amphotericin B, pimaricin, nystatin or natamycin, and more preferably amphotericin B.
  • the azole agent is preferably an imidazole compound such as miconazole, or a triazole compound such as fluconazole, itraconazole, phosphofluconazole or voriconazole.
  • the candy-based drug is preferably micafungin or caspofungin.
  • the fluoropyrimidine-based drug is preferably flucytosine.
  • Amphotericin B a polyene macrolide drug, has high antifungal activity and is useful for the treatment of serious fungal infections, but may show side effects such as nephrotoxicity.
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia), is an antifungal activity of an antifungal drug such as a polyene macrolide drug, an azole drug, a candine drug and a fluoropyrimidine drug. Has the activity of enhancing.
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia), is selected from the group consisting of polyene macrolide agents, azole agents, canin agents and fluoropyrimidine agents.
  • the dose of the antifungal agent that may have side effects can be reduced and / or the duration of administration can be shortened.
  • the occurrence of side effects caused by at least one antifungal drug can be substantially reduced.
  • administering together means administering a plurality of drugs simultaneously or separately (for example, continuously at regular intervals).
  • such an administration form may be referred to as "combination administration”.
  • the combined administration of the compound represented by the formula (I), particularly the compound represented by the formula (Ia) and at least one antifungal drug reduces the dose of the antifungal drug which may have side effects. And / or the administration period can be shortened. As a result, the occurrence of side effects caused by at least one antifungal drug can be substantially reduced.
  • the compound represented by the formula (I), which is the active ingredient of the activity enhancer of the antifungal agent of one aspect of the present invention, particularly the compound represented by the formula (Ia) of one aspect of the present invention is at least one kind. It has the activity of enhancing the antifungal activity of antifungal drugs.
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia) may or may not have antifungal activity by itself.
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia) usually does not have substantially antifungal activity by itself.
  • the compound of formula (I), in particular the compound of formula (Ia), is of at least one antifungal agent, even if it does not have substantially antifungal activity by itself.
  • the antifungal drug Since it has an activity of enhancing antifungal activity, it is necessary to reduce the dose of the antifungal drug which may have side effects and / or shorten the administration period by co-administration with at least one antifungal drug. Can be done. As a result, the occurrence of side effects caused by at least one antifungal drug can be substantially reduced.
  • the antifungal activity of an antifungal agent is, but is not limited to, determined by, for example, the following means.
  • Formula (I) for any test fungus eg, yeast, filamentous and zygomycosis
  • CLSI American Clinical Laboratory Standards Association
  • the compound represented by, particularly the compound represented by the formula (Ia), or at least one antifungal drug is administered.
  • the growth of the fungus is measured using the turbidity (for example, OD 550 ) or the colony diameter as an index, and the inhibition rate (%) is calculated by comparing with the value at the start of culturing.
  • the minimum concentration of a compound having a calculated inhibition rate of a predetermined value (for example, 90%) or more is defined as the minimum inhibitory concentration (MIC value) of the compound.
  • the compound represented by the formula (I) which is the active ingredient of the activity enhancer of the antifungal agent of one aspect of the present invention, particularly according to one aspect of the present invention.
  • the antifungal activity of the compound represented by the formula (Ia) and at least one antifungal drug can be evaluated.
  • the activity of enhancing the antifungal activity of the antifungal drug is, but is not limited to, determined by, for example, the following means. Based on the above means, the MIC value when at least one antifungal drug is administered alone is determined. Then, under the same test conditions, the compound represented by the formula (I), particularly the compound represented by the formula (Ia) of one aspect of the present invention, and at least one antifungal agent are put together (for example, simultaneously).
  • the antifungal activity of at least one antifungal agent of the compound represented by the formula (I), particularly the compound represented by the formula (Ia) of one aspect of the present invention is calculated. For example, when the enhancement rate is doubled, the MIC of at least one antifungal drug when the compound represented by the formula (I), particularly the compound represented by the formula (Ia) of one aspect of the present invention is administered in combination. The value is 1/2 of the MIC value when the antifungal drug is administered alone.
  • At least one antifungal agent administered in combination with the compound represented by the formula (I), particularly the compound represented by the formula (Ia), has a MIC value determined by the above procedure being yeasty.
  • fungi eg Candida albicans
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia) is usually at a concentration of 0.25 ⁇ g / mL or more, for example, 0.5 ⁇ g / mL or more, particularly 1 ⁇ g / mL or more.
  • the antifungal activity of at least one antifungal drug is usually increased by a factor of 2 or more, for example, in the range of 8 to 64 times, particularly in the range of 16 to 32 times.
  • the activity can be enhanced. Therefore, when the enhancement rate is in the above range, the compound represented by the formula (I), particularly the compound represented by the formula (Ia), may have side effects when administered in combination with at least one antifungal drug.
  • the dose of the sexual antifungal drug can be reduced and / or the duration of administration can be shortened. As a result, the occurrence of side effects caused by at least one antifungal drug can be substantially reduced.
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia) When the compound represented by the formula (I), particularly the compound represented by the formula (Ia) is applied for pharmaceutical use, the compound represented by the formula (I), particularly the compound represented by the formula (Ia) It includes not only the compounds themselves, but also pharmaceutically acceptable salts of the compounds and pharmaceutically acceptable solvates thereof.
  • the pharmaceutically acceptable salts of the compound represented by the formula (I), particularly the compound represented by the formula (Ia), and the pharmaceutically acceptable solvates thereof are not limited, but for example. , The salts or solvates exemplified above are preferred.
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia) is in the form of the above-mentioned pharmaceutically acceptable salt or pharmaceutically acceptable solvate, at least one antifungal species.
  • the compound can be applied to the desired pharmaceutical application without substantially reducing the activity of enhancing the antifungal activity of the drug.
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia) is applied to pharmaceutical use.
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia) is used. It includes not only the compound itself, but also the prodrug form of the compound.
  • prodrug means a compound that is converted to a parent drug in vivo.
  • the prodrug form of the compound is not limited, but for example, when a hydroxyl group is present, an ester of the hydroxyl group and an arbitrary carboxylic acid, an amide of the hydroxyl group and an arbitrary amine, or the like can be used.
  • an amino group is present, an amide of the amino group and an arbitrary carboxylic acid can be mentioned.
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia) is in the above-mentioned prodrug form, the compound represented by the parent drug formula (I), particularly the compound represented by the formula (Ia)
  • the pharmacokinetics of the represented compound upon administration of the prodrug form to the subject can be improved without substantially reducing the activity of enhancing the antifungal activity of at least one antifungal agent.
  • the compound When a compound represented by the formula (I), particularly a compound represented by the formula (Ia), is applied to pharmaceutical use, the compound may be used alone, and may be used as one or more pharmaceutically acceptable components. It may be used in combination.
  • the medicament of this embodiment can be formulated in various dosage forms commonly used in the art, depending on the desired method of administration. Therefore, the medicament of this embodiment is also a compound represented by the formula (I), particularly a compound represented by the formula (Ia) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof. And can also be provided in the form of a pharmaceutical composition comprising one or more pharmaceutically acceptable carriers.
  • the pharmaceutical composition of this embodiment comprises one or more pharmaceutically acceptable media (eg, a solvent such as sterile water or a solution such as saline), an excipient, a binder, and the like.
  • a pharmaceutically acceptable media eg, a solvent such as sterile water or a solution such as saline
  • Vehicles solubilizers, preservatives, stabilizers, disintegrants, disintegrant inhibitors, swelling agents, lubricants, surfactants, emulsifiers, oily liquids (eg vegetable oils), suspending agents, buffers, soothing agents, It may contain an antioxidant, a sweetener, a flavoring agent and the like.
  • the preparation is not particularly limited, and may be a preparation for use in parenteral administration or a preparation for use in oral administration.
  • the dosage form of the medicament of this embodiment may be a unit-dose form or a multi-dose form.
  • Formulations for use in parenteral administration include, for example, injectables such as sterile solutions or suspensions with water or other pharmaceutically acceptable media.
  • Ingredients that can be mixed with the injection include, but are not limited to, physiological saline, glucose or other adjuvants (eg, D-sorbitol, D-mannitol, D-mannose or sodium chloride).
  • Vehicles such as isotonic solutions containing, solubilizers such as alcohols (eg ethanol or benzyl alcohol), polyalcohols (eg propylene glycol or polyethylene glycol) or esters (eg benzyl benzoate), polysorbitol 80 TM or poly.
  • Nonionic surfactants such as oxyethylene hydrogenated castor oil, oily liquids such as sesame oil or soybean oil, buffers such as phosphate buffer or sodium acetate buffer, such as benzalconium chloride or prokine hydrochloride. Painless agents, stabilizers such as human serum albumin or polyethylene glycol, preservatives, antioxidants and the like.
  • the prepared injection is usually filled in a suitable vial (eg, ampoule) and stored in a suitable environment until use.
  • preparations for use in oral administration include tablets, pills, powders, capsules, soft capsules, microcapsules, elixirs, liquids, syrups, slurries and suspensions. ..
  • the tablets may be formulated as a dosage form of sugar-coated or soluble-coated sugar-coated tablets, gelatin-encapsulated tablets, enteric-coated tablets, orally disintegrating tablets (OD tablets) or film-coated tablets, if desired. It may be formulated as a dosage form of a heavy tablet or a multi-layer tablet.
  • the components that can be mixed with tablets, capsules, etc. are not limited, but for example, water, ethanol, propanol, simple syrup, glucose solution, carboxymethyl cellulose, cellac, methyl cellulose, potassium phosphate, polyvinylpyrrolidone, etc.
  • Binders such as gelatin, corn starch, traganth gum or gum arabic; excipients such as crystalline cellulose, lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin or stearic acid; dried starch, sodium alginate , Agar powder, laminaran powder, sodium hydrogen carbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, stearic acid monoglyceride, starch, lactose or disintegrants such as polyvinylpyrrolidone; sucrose, stearic acid butter or hydrogenated oil Disintegration inhibitors such as; swelling agents such as corn starch, gelatin or alginic acid; lubricants such as magnesium stearate; absorption enhancers such as quaternary ammonium salts or sodium lauryl sulfate; moisturizers such as glycerin or starch.
  • excipients such as
  • Adsorbents such as starch, lactose, kaolin, bentonite or colloidal silicic acid
  • Lubricants such as purified talc, stearate (eg magnesium stearate), powder borate or polyethylene glycol
  • Sucrose, lactose or Sweeteners such as saccharin
  • flavors such as starch, red mono oil or cherry can be mentioned.
  • the preparation may further contain a liquid carrier such as fat.
  • a drug containing a compound represented by the formula (I), particularly a compound represented by the formula (Ia), a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient is a depot preparation. It can also be formulated as.
  • the drug of this embodiment in the dosage form of the depot preparation can be administered, for example, subcutaneously or intramuscularly, or by intramuscular injection.
  • the activity of enhancing the antifungal activity of at least one antifungal agent of the compound represented by the formula (I), particularly the compound represented by the formula (Ia). can be continuously expressed over a long period of time.
  • the compound When a compound represented by the formula (I), particularly a compound represented by the formula (Ia), is applied for pharmaceutical use, the compound may be provided together with at least one antifungal agent, or separately. May be provided. In either case, it is included in the embodiment of this embodiment.
  • the medicament of this embodiment is a compound represented by the formula (I), particularly the compound represented by the formula (Ia).
  • the medicament of this embodiment is, for example, a compound represented by the formula (I), particularly a compound represented by the formula (Ia) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof.
  • the medicament of this embodiment is represented by the formula (I).
  • At least one antifungal agent comprising at least the compounds represented, in particular the compounds represented by formula (Ia) or pharmaceutically acceptable salts thereof, or their pharmaceutically acceptable solvates. It can be in the form of a pharmaceutical composition.
  • the medicament of this embodiment is, for example, a compound represented by the formula (I), particularly a compound represented by the formula (Ia) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof.
  • the medicament of this embodiment contains only the compound represented by the formula (I), particularly the compound represented by the formula (Ia) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is pharmaceutically acceptable. It can also be provided in the form of a formulation comprising (ie, not containing at least one antifungal agent).
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia), and at least one antifungal agent can be administered in combination.
  • At least one drug containing the compound represented by the formula (I), particularly the compound represented by the formula (Ia), a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient is at least one. It can also be used in combination with one or more other drugs that are useful as medicines other than the species of antifungal drugs.
  • the medicament of this embodiment is a compound represented by the formula (I), particularly a compound represented by the formula (Ia) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is pharmaceutically acceptable.
  • a concomitant drug containing one or more of the other drugs is a compound represented by the formula (I), particularly a compound represented by the formula (Ia) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is pharmaceutically acceptable.
  • the concomitant drug includes one or more compounds represented by the formula (I), particularly a compound represented by the formula (Ia), a pharmaceutically acceptable salt thereof, or a solvate thereof which is pharmaceutically acceptable. It may be in the form of a pharmaceutical composition in combination with the above-mentioned other drug, and the compound represented by the formula (I), particularly the compound represented by the formula (Ia) or a pharmaceutically acceptable salt thereof. Alternatively, it may be in the form of a pharmaceutical composition used in combination with one or more of the other agents, including those pharmaceutically acceptable solvates.
  • the drug of this embodiment is in the form of a combination drug as described above, the compound represented by the formula (I), particularly the compound represented by the formula (Ia) or a pharmaceutically acceptable salt thereof, or a pharmaceutical product thereof.
  • a plurality of formulations in which one or more other agents are separately formulated which may be provided in the form of a single formulation, which comprises the above acceptable solvate and one or more other agents. May be provided in the form of a pharmaceutical combination or kit comprising. In the form of drug combinations or kits, each formulation can be administered simultaneously or separately (eg, sequentially).
  • One type of drug contains a compound represented by the formula (I), particularly a compound represented by the formula (Ia), a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient.
  • the above fungal infections can be prevented or treated in the same manner.
  • Fungi that cause one or more of the fungal infections are, but are not limited to, for example, yeast fungi such as Candida albicans, C. parapsilosis, and Candida grabulata. (C. glabrata) and Cryptococcus neoformans; filamentous fungi, such as Aspergillus fumigatus, Aspergillus flavas, A. niger and Aspergillus teleus.
  • the one or more fungal infections include, but are not limited to, deep mycoses, superficial mycoses and dermatomycoses.
  • the one or more fungal infections are preferably one or more diseases, symptoms or disorders selected from the group consisting of deep mycoses, superficial mycoses and dermatomycoses.
  • the disease, symptom or disorder can be prevented or treated by administering the drug of this embodiment to a subject who needs the prevention or treatment of one or more of the fungal infections.
  • the drug containing the compound represented by the formula (I), particularly the compound represented by the formula (Ia), a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient is described in 1 above. It can be applied to a variety of subjects in need of prevention or treatment of symptoms, diseases and / or disorders that are more than a species of fungal infection.
  • the subject is a human or non-human mammal (eg, a warm-blooded animal such as a pig, dog, cow, rat, mouse, guinea pig, rabbit, chicken, sheep, cat, monkey, cloak or orangutan), or a reptile (eg, a reptile).
  • a subject or patient such as a warm-blooded animal such as a frog, a snake or a lizard.
  • a subject or patient such as a warm-blooded animal such as a frog, a snake or a lizard.
  • prevention means substantially preventing the occurrence (onset or manifestation) of symptoms, diseases and / or disorders.
  • treatment means suppressing (eg, suppressing progression), ameliorating, repairing and / or curing the symptoms, diseases and / or disorders that have occurred (onset or manifest).
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia), is a symptom, disease and / or disorder (eg, deep mycosis) which is one or more fungal infections described above. , Superficial mycosis or dermatomycosis), and can be used for the prevention or treatment of the symptoms, diseases and / or disorders. Therefore, the medicament of this embodiment is preferably a medicament for use in the prevention or treatment of symptoms, diseases and / or disorders which are one or more fungal infections described above, and deep mycosis. It is more preferable that the medicine is used for the prevention or treatment of one or more fungal infections selected from the group consisting of superficial mycosis and dermatomycosis.
  • the symptoms, diseases and / or disorders can be prevented or treated through the activity of the compound to enhance the antifungal activity of at least one antifungal agent.
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia), is a symptom, disease and / or disorder (eg, deep mycosis) which is one or more fungal infections described above. , Superficial mycosis or dermatomycosis), and can be used for the prevention or treatment of the symptoms, diseases and / or disorders. Therefore, another aspect of the invention is an effective amount of formula (I) for a subject in need of prevention or treatment of the symptoms, diseases and / or disorders of one or more fungal infections described above.
  • the compound represented by, particularly the compound represented by the formula (Ia) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof is administered together with at least one antifungal drug.
  • the symptoms, diseases and / or disorders that are one or more fungal infections are one or more symptoms, diseases and / or disorders selected from the group consisting of deep mycosis, superficial mycosis and dermatomycosis. It is preferably an obstacle.
  • the compound represented by the formula (I), particularly the compound represented by the formula (Ia), of the at least one antifungal agent By administering the medicament of the embodiment together with at least one antifungal agent, the compound represented by the formula (I), particularly the compound represented by the formula (Ia), of the at least one antifungal agent.
  • the symptoms, diseases and / or disorders can be prevented or treated through activity that enhances antifungal activity.
  • Another aspect of the invention is a compound of formula (I) for use in the prevention or treatment of symptoms, diseases and / or disorders which are one or more fungal infections described above, in particular.
  • Another aspect of the invention is represented by formula (I) for the manufacture of a medicament for use in the prevention or treatment of symptoms, diseases and / or disorders which are one or more fungal infections described above.
  • the symptoms, diseases and / or disorders that are one or more fungal infections are one or more symptoms, diseases and / or disorders selected from the group consisting of deep mycosis, superficial mycosis and dermatomycosis. It is preferably an obstacle.
  • the activity of the compound represented by the formula (I), particularly the compound represented by the formula (Ia) to enhance the antifungal activity of at least one antifungal agent, the symptoms, diseases and / Or the disorder can be prevented or treated.
  • the subject is a drug containing a compound represented by the formula (I), particularly a compound represented by the formula (Ia) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof as an active ingredient.
  • the exact dose and dosage eg, dose, frequency of administration and / or route of administration
  • especially when administered to human patients is the age, weight, gender, symptoms, diseases and / or disorders to be prevented or treated.
  • the final decision should be made by the attending physician in consideration of the therapeutically effective dose, frequency of administration, route of administration, etc., in consideration of many factors such as the exact condition (for example, severity) of the drug and the route of administration. is there.
  • the compound represented by the formula (I), which is the active ingredient, particularly the compound represented by the formula (Ia) is administered to the subject in a therapeutically effective amount and frequency.
  • the dose of the compound represented by the formula (I), which is the active ingredient, particularly the compound represented by the formula (Ia) is usually per single dose. , 0.001 to 100 mg / kg body weight, typically in the range of 0.01 to 10 mg / kg body weight per dose, especially 0.1 to 10 mg / kg body weight per dose. The range.
  • the number of administrations of the drug of this embodiment can be, for example, once or more than once a day, or once every few days.
  • the route of administration of the drug of this embodiment is not particularly limited, and may be administered orally, or parenterally (for example, intrarectal, intravitreal, intestinal, intramuscular, subcutaneous, intramedullary, intrasheath). , Directly intraventricularly, intravenously, intravitreally, intraperitoneally, intranasally or intraocularly) may be administered single or multiple times.
  • BFM-0088 strain is a fungus isolated from the soil of Tokyo Bay, Tokyo, Japan. Comparison with known bacterial species was performed based on the morphological characteristics, culture properties and physiological properties of the BFM-0088 strain. As a result, it was clarified that this strain is Aspergillus polyporicola. This strain was named BFM-0088 strain.
  • This strain was named Aspergillus polypolycola BFM-0088 as of April 3, 2019, National Institute of Technology and Evaluation Patent Microorganisms Depositary Center (2-5 Kazusakamatari, Kisarazu City, Chiba Prefecture, Japan 292-0818) -It has been deposited internationally in Room 122) based on the Butapest Convention (receipt number NITE ABP-02936).
  • the mycological properties of the BFM-0088 strain are as follows.
  • the BFM-0088 strain grew well on a medium such as a nutrient agar medium such as a PDA medium.
  • a medium such as a nutrient agar medium such as a PDA medium.
  • the conidia were fiaro-type conidia, which were spherical to subspherical in one cell, colorless and had a smooth surface.
  • BLAST homology search for DB-FU 10.0 and international nucleotide sequence database 28S rDNA-D1D2 nucleotide sequence is 100% homologous to the nucleotide sequence of Aspergillus polypolycola NRRL32683 T (accession number EF669595), which is a type of Ascomycota. The rate was shown. In addition, the ITS-5.8 rDNA nucleotide sequence showed a homology rate of 100% with respect to multiple nucleotide sequences of Aspergillus polypolycola, which is a type of Ascomycota. From the above, the BFM-0088 strain was identified as Aspergillus polypolycola.
  • the optimum growth conditions for the BFM-0088 strain were aerobic conditions, pH 5.6 ⁇ 0.2, and temperature 27 ° C.
  • the growth conditions of this strain were aerobic conditions, static culture, pH 3 to 9, temperature 25 to 27 ° C, and culture period of 1 to 2 weeks.
  • the crude extract was dissolved in a small amount of methanol and added to an octadecylsilyl column (3 x 15 cm, Merck) to add 0%, 40%, 60%, 80% and 100% (v / v) aqueous acetonitrile solution. (200 mL for each solvent) was eluted sequentially.
  • the 80% acetonitrile aqueous solution elution fraction (4th fraction) (70 mg) was subjected to reverse phase C-18 high performance liquid chromatography (HPLC) (20 x 250 mm; Senshu Pack PEGASIL ODS SP100, Senshu Science) as follows.
  • compound 1 has a structure represented by the following formula (2E, 6E) -30-(5- (2-hydroxypropan-2-yl)).
  • -2-Methyltetra-2-yl) -3,7,11,15,19,23,27-Heptamethyltriaconta-2,6-diene-1,11,15,19,23,27-Hexaol
  • the structure was determined to be.
  • compound 2 has a structure represented by the following formula (2E, 6E, 10E) -30-(5- (2-hydroxypropane-2-).
  • 2E, 6E, 10E -30-(5- (2-hydroxypropane-2-).
  • Il) -2-methyltetra-2-yl) -3,7,11,15,19,23,27-Heptamethyltriaconta-2,6,10-triene-1,15,19,23,27-
  • the structure was determined to be pentaol.
  • compound 3 was identified as (2E, 6E, 10E) -3,7,11,15,19 of a known compound having a structure represented by the following formula. , 23,27,31,35-Nonamethylhexatriaconta-2,6,10-Triene-1,15,19,23,27,31,34,35-Octaol was identified.
  • RPMI 1640 powder medium was purchased from GIBCO. 3-Morpholine propanesulfonic acid (MOPS) was purchased from DOJINDO. Sodium chloride was purchased from Kanto Chemical Co., Inc. DMSO was purchased from Nacalai Tesque. Allermar Blue was purchased from Bio-Rad.
  • MOPS 3-Morpholine propanesulfonic acid
  • a YAZAWA automatic mixer was used as the vortex mixer.
  • a Bio Tek Power Wave x340 was used to measure the absorbance.
  • NS-4P manufactured by AS ONE Corporation was used.
  • N-Biotek's NB-203 was used as the incubator for the 96-well plate (As One).
  • the 150 mm bottle top filter (pore diameter 0.22 mm), 15 mL centrifuge tube and 50 mL centrifuge tube were purchased from Corning.
  • Test bacteria Laboratory-owned Candida albicans ATCC 90029 and Rhizopus oryzae NBRC 4705 were used as the test bacteria.
  • Amphotericin B was prepared in 0.8 mg / mL DMSO solution.
  • the test compounds (Compounds 1 and 2) were prepared in 6.4 mg / mL DMSO solution, respectively. Both solutions were stored at -20 ° C after preparation.
  • Physiological saline (0.85% aqueous sodium chloride solution) and bamboo skewers were sterilized by high pressure steam (121 ° C., 15 minutes), and then stored at room temperature.
  • Test II-1 Activity evaluation test of antifungal active substance
  • preparation of bacterial solution The method for preparing the inoculated bacterial solution of Candida albicans is shown below. In a sterilized 15 mL centrifuge tube (Corning), 5 mL of 0.85% sterile saline was measured. Five Candida albicans colonies (about 1 mm in diameter) were collected using a sterilized bamboo skewer and suspended in the measured sterile saline solution. This was vortexed for 15 seconds using an automatic mixer (YAZAWA). 100 ⁇ L of this suspension was dispensed into a sterilized 96-well plate (As One), and then OD 550 was measured.
  • YAZAWA automatic mixer
  • the resulting suspension was diluted 100-fold with RPMI 1640 medium. This 100-fold dilution was further diluted 20-fold with RPMI 1640 medium.
  • the obtained diluted solution was used as an inoculum solution.
  • the antifungal spectrum was measured by the Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard --Third Edition, Wayne according to the American Clinical and Laboratory Standards Institute (CLSI) M27-A3 and M38-A2 methods. , PA, 28, M27-A3 (2008), Filamentous Fungi; Approved Standard-Second Edition Wayne, PA, 28, M38-A2 (2008)).
  • 1.0 ⁇ L of a diluted solution of the test compound prepared by DMSO was added so that the final concentration of the test compound was 32, 16, 8.0... 0.016 ⁇ g / mL.
  • 1.0 ⁇ L of DMSO alone was added.
  • Each test plot and control plot were prepared with 8 wells.
  • Candida albicans was then added to each well at a ratio of 19 ⁇ L of RPMI 1640 medium and 180 ⁇ L of inoculum solution. After the addition, the OD 550 of each well was measured (this was taken as the initial turbidity).
  • Candida albicans inoculated into wells of 96-well plates was cultured at a temperature of 35 ° C. for 72 hours. Then, using NS-4P (As One), the 96-well plate was shaken and stirred for 30 minutes. After stirring, OD 550 of each well was measured (this was defined as terminal turbidity). The inhibition rate of each compound was calculated based on the following formula (M-2). The minimum concentration of the compound having the calculated inhibition rate of 90% or more was defined as the minimum inhibitory concentration (MIC value) of the compound.
  • Test II-2 Evaluation test of enhancing activity against the antifungal agent amphotericin B
  • Inoculum solutions of Candida albicans and Risopas oryzae were prepared in the same procedure as in Test II-1.
  • DMSO alone 2.0 ⁇ L was added.
  • One well of each test plot and eight wells of control plot were prepared.
  • Candida albicans was then added to each well at a ratio of 18 ⁇ L of RPMI 1640 medium and 180 ⁇ L of inoculum solution. After the addition, the OD 550 of each well was measured (this was taken as the initial turbidity).
  • NB-203 N-Biotek
  • Candida albicans inoculated into wells of 96-well plates was cultured at a temperature of 35 ° C. for 24 hours. Then, using NS-4P (As One), the 96-well plate was shaken and stirred for 30 minutes.
  • the method for evaluating the amphotericin B activity enhancing effect of the test compounds (Compounds 1 and 2) on lysopath oryzae is shown below.
  • the test compound, a diluted solution of amphotericin B, and control DMSO were dispensed into predetermined wells of a 96-well plate.
  • Risopath oryzae was added to the given wells at a ratio of 93 ⁇ L of RPMI 1640 medium and 100 ⁇ L of inoculum solution. Then 5 ⁇ L of Alamar Blue was added.
  • the minimum concentration of amphotericin B when the calculated inhibition rate was 80% or more was defined as the MIC value of amphotericin B in the combined administration of each test compound and amphotericin B.
  • the amphotericin B activity enhancement rate of each test compound was calculated based on the above formula (M-4). The calculation of the amphotericin B activity enhancement rate of each test compound was repeated three times.
  • Table 1 shows the MIC value of amphotericin B when the test compound and amphotericin B were co-administered to Candida albicans.
  • Table 2 shows the MIC value of amphotericin B when the test compound and amphotericin B were co-administered to lysopath oryzae.
  • the column of "test compound concentration” is the concentration of the test compound when the test compound and amphotericin B are co-administered
  • the column of "MIC” is the MIC of amphotericin B when the test compound and amphotericin B are co-administered.
  • the value and the column of "enhancement rate” indicate the amphotericin B activity enhancement rate by each concentration of the test compound.
  • the antifungal activity of amphotericin B against Candida albicans was increased 2-64 times by co-administration of compounds 1, 2 or 3 of 0.25 ⁇ g / mL, especially 0.5 ⁇ g / mL or more, with amphotericin B. In particular, it was enhanced 8 to 64 times.
  • the antifungal activity of amphotericin B against amphotericin B is increased by co-administering compounds 1, 2 or 3 of 0.25 ⁇ g / mL, especially 0.5 ⁇ g / mL or more, in combination with amphotericin B. It was increased 16 times, especially 4 to 16 times.
  • the present invention is not limited to the above-described embodiment, and includes various modifications.
  • the above-described embodiment has been described in detail in order to explain the present invention in an easy-to-understand manner, and is not necessarily limited to those having all the described configurations.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Le but de la présente invention est de fournir un nouveau composé qui a l'action d'amplifier efficacement l'activité antifongique d'un médicament antifongique et qui a une structure de squelette différente de celle des composés pharmaceutiques connus. Un mode de réalisation de la présente invention concerne le composé représenté par la formule (Ia) [dans la formule, R1'-R35a sont tels que définis dans la description ou les revendications] ou un sel de celui-ci, ou un solvate de celui-ci. Un autre mode de réalisation de la présente invention concerne : une méthode de fabrication du composé, etc. représenté par la formule (Ia) ; un amplificateur d'activité d'au moins un type de médicament antifongique, l'amplificateur d'activité contenant, en tant que principe actif, le composé représenté dans la formule (I) [dans la formule, R1'-R35 sont tels que définis dans la description ou les revendications] ou un sel de celui-ci, ou un solvate de ceux-ci ; et un médicament ou une composition pharmaceutique contenant ledit composé en tant que principe actif.
PCT/JP2020/019174 2019-05-15 2020-05-14 Nouveau composé polyterpénoïde ayant une action amplifiant l'activité d'un médicament antifongique, et sa méthode de production WO2020230833A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019092118A JP7256527B2 (ja) 2019-05-15 2019-05-15 抗真菌薬に対する活性増強作用を有する新規ポリテルペノイド化合物及びその製造方法
JP2019-092118 2019-05-15

Publications (1)

Publication Number Publication Date
WO2020230833A1 true WO2020230833A1 (fr) 2020-11-19

Family

ID=73220941

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/019174 WO2020230833A1 (fr) 2019-05-15 2020-05-14 Nouveau composé polyterpénoïde ayant une action amplifiant l'activité d'un médicament antifongique, et sa méthode de production

Country Status (2)

Country Link
JP (1) JP7256527B2 (fr)
WO (1) WO2020230833A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6183196A (ja) * 1985-07-26 1986-04-26 Banyu Pharmaceut Co Ltd 抗真菌剤
JPH07126202A (ja) * 1993-11-05 1995-05-16 Takeda Chem Ind Ltd 化合物ｔａｎ−１７８６およびその用途
JP2018111670A (ja) * 2017-01-13 2018-07-19 学校法人北里研究所 抗真菌薬に対する活性増強作用を有する新規化合物及びその製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6183196A (ja) * 1985-07-26 1986-04-26 Banyu Pharmaceut Co Ltd 抗真菌剤
JPH07126202A (ja) * 1993-11-05 1995-05-16 Takeda Chem Ind Ltd 化合物ｔａｎ−１７８６およびその用途
JP2018111670A (ja) * 2017-01-13 2018-07-19 学校法人北里研究所 抗真菌薬に対する活性増強作用を有する新規化合物及びその製造方法

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BIREN K JOSHI; JAMES B GLOER; DONALD T WICKLOW: "New Verticillin and Glisoprenin Analogues from Gliocladium catenulatum, a Mycoparasite of Aspergillus flavus Sclerotia", JOURNAL OF NATURAL PRODUCTS, vol. 62, no. 5, 1 May 1999 (1999-05-01), pages 730 - 733, XP055028526, ISSN: 0163-3864, DOI: 10.1021/np980530x *
CHOOCHUAY JUTATIP; XU XIN; RUKACHAISIRIKUL VATCHARIN; GUEDDUAYTHONG PIYADA; PHONGPAICHIT SOUWALAK; SAKAYAROJ JARIYA; CHEN JING; SH: "Curvularin derivatives from the soil-derived fungus Aspergillus polyporicola PSU-RSPG187", PHYTOCHEMISTRY LETTERS, vol. 22, 1 January 2017 (2017-01-01), pages 122 - 127, XP085283787, ISSN: 1874-3900, DOI: 10.1016/j.phytol.2017.09.011 *
DATABASE Nucleotide [online] 8 April 2016 (2016-04-08), ANONYMOUS: "Aspergillus polyporicola isolate NRRL 32683 internal transcribed spacer 1, 5.8S ribosomal RNA gene , and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene", XP055760427, retrieved from NCBI Database accession no. EF669595.1 *
ECKHARD THINES; FRANK EILBERT; HEIDRUN ANKE; OLOV STERNER: "Glisoprenins C, D and E, New Inhibitors of Appressorium Formation in Magnaporthe grisea, from Cultures of Gliocladium roseum", THE JOURNAL OF ANTIBIOTICS, vol. 51, no. 2, 30 November 1997 (1997-11-30), pages 117 - 122, XP009524637, ISSN: 0021-8820, DOI: :10.7164/antibiotics.51.117 *
OLOV STERNER; ECKHARD THINES; FRANK EILBERT; HEIDRUN ANKE: "Glisoprenins C, D and E, New Inhibitors of Appressorium Formation in Magnaporthe grisea, from Cultures of Gliocladium roseum", THE JOURNAL OF ANTIBIOTICS, vol. 51, no. 2, 1 February 1998 (1998-02-01), pages 228 - 231, XP009524638, ISSN: 0021-8820, DOI: 10.7164/antibiotics.51.228 *
ROY, S.K. ET AL.: "The Structure of Neo- Enactin A, A New Antifungal Antibiotic Potentiating Polyene Antifungal Antibiotics", J. ANTIBIOTICS, vol. 39, no. 5, 1986, pages 717 - 720, XP055760432 *
SCOTT A NEFF; SANG UN LEE; YUKIHIRO ASAMI; JONG SEOG AHN; HYUNCHEOL OH; JONAS BALTRUSAITIS; JAMES B GLOER; DONALD T WICKLOW: "Aflaquinolones A-G: Secondary Metabolites from Marine and Fungicolous Isolates of Aspergillus spp.", JOURNAL OF NATURAL PRODUCTS, vol. 75, no. 3, 2012, pages 464 - 472, XP055087611, ISSN: 0163-3864, DOI: 10.1021/np200958r *
SHUN UTSUGI; SATOSHI OTE; HIROSHI DONADA: "22PO-am091 Fungal glisoprenin enhances osteoblastic differentiateon of ST2 cells", ABSTRACT OF THE 139TH ANNUAL MEETING OF THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 139, no. 2, 5 March 2019 (2019-03-05), pages 172, XP009525216 *
STEPHEN W PETERSON : "Phylogenetic Analysis of Aspergillus Species Using DNA Sequences From Four Loci", MYCOLOGIA, vol. 100, no. 2, 1 March 2008 (2008-03-01), pages 205 - 22, XP002672700, ISSN: 0027-5514, DOI: 10.3852/mycologia.100.2.205 *
TAKAMATSU SUSUMU : "Introductory Lecture on Plant Disease Control: Plant pathogen phylogenetic trees -- Systems and Examination (1) Fundamentals of Molecular Phylogenetics", PLANT PROTECTION, vol. 59, no. 3, 2005, pages 64 - 69, XP009524642, ISSN: 0037-4091 *
TAKASHI SUGITA , AKEMI NISHIKAWA : "Molecular Taxonomy and Identification of Pathogenic Fungi Based on DNA Sequence Analysis", JAPANESE JOURNAL OF MEDICAL MYCOLOGY, vol. 45, no. 2, 1 January 2004 (2004-01-01), pages 55 - 58, XP055760439 *

Also Published As

Publication number Publication date
JP7256527B2 (ja) 2023-04-12
JP2020186206A (ja) 2020-11-19

Similar Documents

Publication Publication Date Title
CN108640968B (zh) 一种混源萜类化合物及其在制备抗炎药物中的用途
JP6969770B2 (ja) 抗真菌薬に対する活性増強作用を有する新規化合物及びその製造方法
WO2020230833A1 (fr) Nouveau composé polyterpénoïde ayant une action amplifiant l'activité d'un médicament antifongique, et sa méthode de production
CN111278985B (zh) 具有针对鸟分枝杆菌复合体感染疾病治疗活性的新型化合物及其制造方法
JP7046344B2 (ja) 抗真菌薬に対する活性増強作用を有する新規環状ペプチド化合物及びその製造方法
US20220119402A1 (en) Turbinmicin compounds, compositions and uses thereof
JP7138941B2 (ja) ステロールｏ－アシルトランスフェラーゼ２（ｓｏａｔ２）阻害活性を有する新規化合物及びその製造方法
JP6945216B2 (ja) ステロールｏ−アシルトランスフェラーゼ２（ｓｏａｔ２）阻害活性を有する新規化合物及びその製造方法
EP2468718A1 (fr) Cabanillasin, un nouveau composé antifongique produit par Xenorhabdus cabanillasii entomopathogène
AU767250B2 (en) Novel compound F-15078
US6818614B2 (en) Compounds having antifungal activity
JP2006528664A (ja) ポリエンポリケチド、その調製方法及び医薬品としてのその使用
EP3601246B1 (fr) Dérivés de 16-méthyl-oxacyclohexadécan-2-one et de 16-methyl-azacyclohexadecan-2-one en tant qu'agents antimicrobiens
EP3708162A1 (fr) Macrocycles avec activités antioxydantes et neuroprotectrices
JP5843188B2 (ja) 抗真菌剤の活性増強作用を有する新規物質およびその製造方法と用途
WO2011009899A2 (fr) Phénalénones comme agents antitumoraux
JP4395579B2 (ja) 抗真菌性化合物
JP2004168685A (ja) 新規化合物ｆ−２０９１６ａ
JP2002255996A (ja) 新規化合物ｆ−１５０７８ｃ及びｆ−１５０７８ｄ
WO2011136174A1 (fr) Composé de depsipeptide
WO2002020816A1 (fr) Nouveau compose f-15949
JPH10114786A (ja) 新規抗真菌化合物
JP2002326952A (ja) 新規化合物ｆ−１５０７８を含有する真菌感染症治療剤
JP2006056806A (ja) Ｆ−９１４９５ａおよびその製造方法
JP2001139597A (ja) 新規化合物ｆ−１５０７８

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20805500

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20805500

Country of ref document: EP

Kind code of ref document: A1